Document:

EX-10.6

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

Exhibit 10.6 

LICENSE AGREEMENT 
 This
LICENSE AGREEMENT (this “Agreement”) is made and entered into as of June 29, 2015 (the “Effective Date”), by and among scPharmaceuticals Inc., having an address at 131 Hartwell Avenue, Suite 215,
Lexington, MA 02421 (“scPharma”) and Sensile Medical AG, having an address at Fabrikstrasse 10, CH-4614 Hägendorf, Switzerland (“Sensile Med”) and Sensile Holding AG
(“Sensile Holding”) and Sensile Patent AG (“Sensile Patent”), both having an address at Zuger Strasse 76b, CH-6340, Baar, Switzerland (Sensile Med, Sensile Holding and Sensile
Patent together in any combination, “Sensile”) (each of scPharma, Sensile Med, Sensile Holding and Sensile Patent, a “Party” and, collectively, the “Parties”), 

WITNESSETH 
 WHEREAS,
the Parties have executed a Strategic Partnership Agreement dated March 18, 2013 (the “Original Partnership Agreement”) and an amendment to the Original Partnership Agreement dated January 31, 2014 (the Original
Partnership Agreement as amended shall be referred to herein as the “Partnership Agreement”); 
 WHEREAS, the
Parties have executed a Device Development Agreement pertaining to a Drug/Device combination for loop diuretics dated March 22, 2013 (the “Original Development Agreement”), an amendment to the Original Development Agreement on
July 29th 2013, and a second amendment on February 17, 2014 (the Original Development Agreement as amended shall be referred to herein as the “Development Agreement”); 

WHEREAS, scPharma and Sensile Holding have executed a Development Option Agreement dated June 24, 2013 (“Original Option
Agreement”) and a Notice of Exercise of Option to Develop and Commercialize dated October 31, 2013 (“Notice of Exercise”) (the Original Option Agreement together with the Notice of Exercise shall be referred to herein
as the “Option Agreement”); 
 WHEREAS, the Parties have executed an Omnibus Amendment dated February 28, 2014,
amending and clarifying provisions in said agreements; 
 WHEREAS, the Partnership Agreement together with the Development Agreement
and Option Agreement, as amended by the Omnibus Amendment, shall be referred to herein as the “Original Agreements”; 

WHEREAS, Sensile is the developer and manufacturer of advanced drug delivery devices, and owns certain technology relating to the Pump
(as defined herein) and related mechanisms which collectively constitute a Device (as defined herein); 
 WHEREAS, scPharma is a
biotechnology company developing biopharmaceutical drug/device products; and 
 WHEREAS, the Parties are collaborating on the
development and commercialization of certain drug/device combinations with scPharma contributing Drug-related development and Sensile contributing Device-related development. 

 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other
good and valuable consideration, the sufficiency of which is acknowledged, the Parties hereby agree as follows: 

1.    DEFINITIONS 

The following terms shall have the meanings assigned to them below for purposes of this Agreement: 

“Affiliate” means any corporation or non-corporate entity, which directly or
indirectly controls, is controlled by, or is under common control with a Party. A corporation or noncorporate entity shall be regarded as in control of another corporation if it owns or directly or indirectly controls at least fifty percent (50%) of
the voting stock of the other corporation or (i) in the absence of the ownership of at least fifty percent (50%) of the voting stock of a corporation or (ii) in the case of a non-corporate entity,
the power to direct or cause the direction of the management and policies of such corporation or non-corporate entity, as applicable. 

“Clinical Trial” means a clinical study designed to investigate the safety, efficacy, economic or other aspects of a
treatment, which may be conducted in support of Regulatory Approval, for marketing purposes or to investigate the utility in a particular clinical setting. For purposes of clarity, Clinical Trials include phase I, phase II, phase III or phase IV
clinical trials. 
 “Confidential Information” means, subject to the exceptions set forth in the following sentence, any
information or data, regardless of whether it is in tangible form, disclosed by either Party (the “Disclosing Party”) that the Disclosing Party has either marked as confidential or proprietary, or has identified in writing as
confidential or proprietary within thirty (30) days of disclosure to the other Party (the “Receiving Party”); provided, however, that information or data related to or regarding a Disclosing Party’s business plans,
strategies, technology, research and development, current and prospective customers, and products or services shall be deemed Confidential Information of the Disclosing Party even if not so marked or identified, unless such information is the
subject of any of the exceptions set forth in the following sentence. Information and data will not be deemed Confidential Information hereunder if such information: (a) is known to the Receiving Party prior to receipt from the Disclosing Party
directly or indirectly from a source other than one having an obligation of confidentiality to the Disclosing Party; (b) becomes known (independently of disclosure by the Disclosing Party) to the Receiving Party directly or indirectly from a
source other than one having an obligation of confidentiality to the Disclosing Party; (c) becomes publicly known or otherwise ceases to be secret or confidential, except through a breach of this Agreement by the Receiving Party; or (d) is
independently developed by the Receiving Party without use of the Disclosing Party’s Confidential Information. 

“Control” or “Controlled” means that a party has the right, without needing to seek further consent, or to
otherwise breach any obligation upon it, to transfer, disclose, license or make available to another the relevant right or asset (as the context requires). 

“Cover” means with respect to any product, component or process, that an Intellectual Property Right (or, if such
Intellectual Property Right is a Patent Right, that a valid claim of such Patent Right) owned or Controlled by a Party would, absent a license thereunder or ownership thereof, be infringed or misappropriated by the use, development, having
developed, making, having made, sell, having sold, offering for sale, importing, having imported, exporting, having exported or otherwise exploiting or having exploited of a product, component or process in the

  
 2 

 
Territory in the Field of Use, provided however, that in determining whether a valid claim that is a claim of a pending patent application would be infringed, it shall be treated as if issued as
then currently prosecuted. Cognates of the word “Cover” shall have correlative meanings. 
 “Develop” means to
discover, research, design or otherwise develop the Device or a process to produce the Device, or perform regulatory activities or production planning for the Device, in accordance with a Development Plan. “Development” means any
and all activities directed to the discovery, research, design, development, regulatory activities and production planning of the Device, as mutually agreed upon by the Parties in a Development Plan. 

“Development Plan” means a plan containing the description of the Development activities for the Device. 

“Device” means a mini drug delivery pump device that includes a Pump, Disposable Component and Reusable Component and other
components. 
 “Disposable Component” shall mean a device component comprised of the Pump, fluid path and other components,
that is designed to be (i) combined with the Reusable Component, (ii) suitable for single-use administration of a Drug and (iii) discarded or recycled after such use. 

“Drug” means any biopharmaceutical product that scPharma wishes to develop for subcutaneous administration by means of a
drug/device combination. 
 “Excluded Field” means (i) pharmaceutical products for the treatment of diabetes based on
the SenseCore Technology, (ii) use with dopaminergic therapy based on the SenseCore Technology, (iii) oncology drugs and biosimilars thereof based on the SenseCore Technology, (iv) to the extent exclusivity has been granted to a Third
Party under an existing agreement with Sensile as of the Effective Date of the Omnibus Amendment, diabetes, neurology, pain management, general infusion, enteral nutrition, dopaminergic therapy, oncology and neonatology, and (v) to the extent
exclusivity may be granted to a Third Party by Sensile in the future, products outside the Exclusive Areas. 
 “Exclusive
Areas” means Generics in the field of 
 (i)    loop diuretics, 

(ii)    glycopeptide antibiotics, 

(iii)    cephalosporins, 

(iv)    inotropes, vasopressors, anti-arrythmics, heart failure medications and calcium channel blockers,
in each case, for cardiovascular diseases, 
 (v)    antibiotics, antifungals and antivirals, in each
case, for infectious diseases, 
 (vi)    infertility medications and iron chelation therapies, in each
case, for hematology or infertility that are suitable for subcutaneous administration and 

(vii)    pandemic response applications and projects funded by the US government or other US public source

  
 3 

 “FDA” means the United States Food and Drug Administration or any successor
agency thereto. 
 “Field of Use” means Development and commercialization of a Product for subcutaneous administration
based on the SenseCore Technology, in the Exclusive Areas. 
 “Generic” or “Generics” means a drug or
biologic which is no longer subject to patent or regulatory exclusivity. 
 “Improvement” means any invention or discovery
that is conceived or first reduced to practice during performance of the Development activities, whether invented or discovered solely by scPharma, solely by Sensile or jointly by scPharma and Sensile. 

“Intellectual Property Rights” means (i) Patent Rights, (ii) Know-How,
(iii) rights associated with Know-How that are works of authorship including copyrights, copyright applications, and copyright registrations; and (iv) rights in any trade names, trademarks, service
marks, domain names, logos, trade dress and brand features. 
 “Know-How” means all
information, whether tangible or intangible and whether patentable or not patentable, including inventions, technologies, know-how, research and formulation methods, proprietary information, processes,
procedures, techniques, algorithms, programs, discoveries, improvements, devices, pharmaceuticals, biologics, products, concepts, designs, prototypes, samples, ideas, models, technical information, materials, drawings, specifications, trade secrets,
data and results. 
 “Laws” means all applicable laws, regulations, rules or orders. 

“NDA” means a New Drug Application submitted to the FDA in the United States in accordance with the United States Federal
Food, Drug and Cosmetic Act, as amended, and the rules and regulations promulgated thereunder, with respect to a pharmaceutical product. 

“Net Sales” shall mean the gross amount received by scPharma or its Affiliate from a Third Party for the applicable Product,
less the following; 
 (a)    the cost of the applicable Device and other fees paid by scPharma to Sensile; 

(b)    any payment (including, but not limited to, royalties or other license fees) to one or more Third Parties to
obtain a patent license in the absence of which scPharma could not legally make, import, use, sell, or offer for sale the Product that includes the applicable Device; 

(c)    customary trade, quantity, or cash discounts to the extent actually allowed and taken; 

(d)    amounts repaid or credited by reason of rejection or return; 

(e)    any taxes or other governmental charges levied on the production, sale, transportation, delivery, or use of a
Product which is paid by or on behalf of scPharma; and 

  
 4 

 (f)    outbound transportation and distribution costs prepaid or allowed and
costs of insurance in transit. 
 “Patent Rights” shall mean (i) all patents and patent applications in any country or
supranational jurisdiction; and (ii) any provisionals, substitutions, divisions, continuations, continuations in part, reissues, renewals, registrations, confirmations, reexaminations, extensions, supplementary protection certificates and the
like, of any such patents or patent applications. 
 “Pre-Existing Intellectual
Property” shall mean any and all Intellectual Property Rights existing as of March 18,2013. 
 “Product”
means a combined product consisting of a Drug and a Device. 
 “Pump” means the disposable rotary-piston pump developed and
owned or controlled by Sensile for use in the Device. 
 “Regulatory Approval” means the approvals, licenses,
registrations, or authorizations granted or issued by any national, regional, state or local governmental entities and agencies, necessary for the development, registration, manufacture, use, transport, export, import, promotion or sale of the
Product in a country, including pricing and reimbursement approvals to the extent the applicable regulatory authorities in such country require a pricing or reimbursement approval prior to commercialization of a Product in such country. 

“Regulatory Authority” means any applicable regulatory and/or governmental body or bodies having jurisdiction over a Drug,
the Device or the Product in the Territory. 
 “Reusable Component” shall mean a device component comprised of the motor,
battery, electronics for operations and other components, that is designed to be (i) combined with the Disposable Component and (ii) suitable for multiple Drug administration when used with the Disposable Component. 

“scPharma Inventions” shall mean all Intellectual Property Rights comprising or in, to or that claim or Cover any and all
(a) Products, (b) components of any and all Products, (c) Drugs, and (d) Improvements of any and all of the foregoing, in each case, which result or arise from the Development activities (including in the development, testing or
manufacture of any of the foregoing), whether by Sensile or scPharma, or their respective personnel or subcontractors, jointly or individually. scPharma Inventions do not include any technology specifically described under Sensile Inventions. 

“SenseCore Technology” means the Intellectual Property Rights Covering the Pump. 

“Sensile Inventions” means all Intellectual Property Rights comprising or in, to, or that claim or Cover (a) the Device,
(b) manufacturing processes for the Device, and (c) Improvements of any and all of the foregoing, in each case, which result or arise from the Development activities, whether by Sensile or scPharma, or their respective personnel or
subcontractors, jointly or individually and which are not specific to the Device, including without limitation the patents listed on Schedule 1.1. 

  
 5 

 “Sensile Pre-Existing Intellectual
Property” means Pre-Existing Intellectual Property, owned or Controlled by Sensile Med, Sensile Holding or Sensile Patent, including the Intellectual Property Rights listed on
Schedule 1.2. 
 “Supply Cost” means the cost of the applicable Device and other fees paid
by scPharma to Sensile and/or to other manufactures of the Device and/or its components. 
 “Term” means as defined in
Section 10 below. 
 “Territory” means worldwide. 

“Third Party” means any party other than Sensile, scPharma and their respective 

2.    LICENSE 

2.1    Exclusive License Grant, During the Term and subject to the terms of this Agreement, Sensile hereby grants
and agrees to grant to scPharma an exclusive (even as to Sensile), worldwide license, with a limited right to sublicense (as described below), under the Sensile Pre-Existing Intellectual Property and Sensile
Inventions, to use, have used, Develop, have Developed, sell, offer for sale, import and export the Products, Devices and subsequent modifications, enhancements, improvements or versions thereof in the Field of Use, including to perform the
Development activities required to commercialize Products in the Field of Use (the “License”). 

2.2    Manufacturing License Grant. In the event scPharma engages itself or an alternative supplier, effective upon
the date of notice delivered to Sensile by scPharma therefor (“Alternative Supplier Notice”), Sensile hereby grants and agrees to grant to scPharma an exclusive, worldwide license, with a limited right to sublicense (as described
below), under the Sensile Pre-Existing Intellectual Property and Sensile Inventions to make or have made Products, Devices and subsequent modifications, enhancements, improvements or versions thereof in the Field of Use (“Manufacturing
License”). The Manufacturing License shall become part of the License on the date of the Alternative Supplier Notice. Sensile shall have the right to approve each alternative supplier, which approval shall not be unreasonably withheld or
delayed. Sensile shall provide such alternative supplier with sufficient information to permit such alternative supplier to manufacture the Device, and shall exercise best efforts to support the manufacture of the Device by such supplier. [***].

 2.3    Sublicensing. Sensile hereby grants and agrees to grant to scPharma, subject to these limitations, the
exclusive right to sublicense its rights under the License to make, have made, sell, offer for sale, import and export Products, Devices and subsequent modifications, enhancements, improvements or versions thereof by an Affiliate or Third Party
manufacturer or distributor, in each case, on behalf of scPharma, in the Field of Use (License and such right to sublicense, the “Exclusive License”). 

2.4    Exclusivity. The continuation of exclusivity in the Exclusive License shall be subject to
Section 2.6. In the event additional exclusive fields are added in accordance with Section 2.7, the License shall be exclusive as agreed by the Parties for such Additional Field (defined below), and the definitions of
Exclusive Areas and Field of Use shall be deemed to include such, additional exclusive fields. 

  
 6 

 2.5    No Implied Licenses. Except as expressly set forth in this
Agreement, neither Party shall be deemed to have granted to the other Party (by implication, estoppel or otherwise), any other licenses, rights, title, or interest in or to any other Intellectual Property Rights Controlled by a Party. 

2.6    Exclusivity Lapses. Exclusivity of the License shall be subject to the achievement of the following
milestones. At all times, Sensile shall work diligently with scPharma to Develop and commercialize Products and Devices in the Field of Use. In the event of a delay in the Development timelines attributable to Sensile or factors outside of
scPharma’s control, the Parties will work together in good faith to adjust such timelines and corresponding milestones. In the event that any of these milestones are not met, scPharma will have [***] after the applicable milestone to submit a
written plan to Sensile for the achievement of such milestone. scPharma and Sensile will negotiate in good faith for up to [***] the plan for the achievement of the milestone. If scPharma does not achieve the milestone by the end of such [***]
negotiation period or, if later, the date on which the Parties agree in writing, only Sensile shall have the right to determine the following: That the exclusivity of the Exclusive License shall lapse with respect to the applicable country or
territory and the applicable Exclusive Area and such portion of the Exclusive License shall become non-exclusive, in each case effective upon receipt by scPharma of a notice (the “Conversion
Notice”) therefor. Such expiration of exclusivity shall not affect scPharma’s right, and Sensile’s obligation to work with scPharma, under this Agreement and the Original Agreements to research and develop any Device, and the
Parties will continue to research and develop such Device in accordance with the terms and conditions of this Agreement and the applicable Development Plan. Exclusivity of the License shall lapse on an Exclusive Area-by-Exclusive Area basis in accordance with the following terms. 

(a)    Loop Diuretics Exclusivity. The License shall convert from an exclusive license to a non-exclusive license in the field of loop diuretics in the event scPharma does not meet the following milestones: 

(i)    the filing with the FDA of an NDA, as appropriate, or filing with the appropriate Regulatory
Authority in the European Union of a similar application or filing (including a CE marking application), in either case for a Product in the field of loop diuretics [***]; 

(ii)    the first commercial sale in the United States or European Union, as applicable, of a Product
within twelve (12) months after Regulatory Approval for sales of a Product in the field of loop diuretics in the United States or European Union; provided, however, that if such milestone is not achieved, only exclusivity in the applicable
country or geographic territory in which the milestone was not achieved shall expire; 
 (iii)    [***];

 (iv)    the failure to file an NDA or CE mark application in the United States or European Union
(each a “Major Market Territory”), as applicable, within twelve (12) months after first commercial sale of the applicable Product in the first Major Market Territory for which such an application was filed pursuant to
clause (i) above; provided, however, that if such milestone is not achieved, only exclusivity in the applicable country or geographic territory for which the applicable application has not been filed shall expire, 

  
 7 

 (v)    for countries outside the United States and European
Union, the failure to initiate a regulatory filing within twenty-four (24) months after the first commercial sale of the applicable Product in the United States; provided, however, that if such milestone is not achieved, only exclusivity in the
country or territory for which a regulatory filing was not initiated shall expire; and 
 (vi)    the
failure of the FDA to approve the Product within twenty-four (24) months after filing the applicable NDA; provided however, that if such milestone is not achieved, only exclusivity in the United States shall expire. 

2.7    Additional Fields. 

(a)    From time to time scPharma may wish to Develop or commercialize a drug-device combination based on an existing
Device for subcutaneous administration based on the SenseCore Technology in fields outside the then-current Field of Use, excluding the Excluded Field (“Additional Field”). In that event, scPharma will provide Sensile written notice
of its intentions and the applicable Additional Field. Sensile will respond to such notice within [***] to: (i) if Sensile has an alternate business interest pertaining to a drug/device combination that would preclude scPharma’s
development and commercialization plan, Sensile shall so inform scPharma, or (ii) if Sensile does not have such an interest, Sensile will send scPharma a notice of acceptance (“Notice of Acceptance”) and grant scPharma a
period of exclusive evaluation and negotiation for [***], during which Sensile and its Affiliates will cooperate in good faith with scPharma with respect to the evaluation of the intended Product. In the event that the Development of any such
Product requires additional Development activities, the Parties shall negotiate in good faith a Development Plan for such Product within [***] of the date of the Notice of Acceptance from Sensile and negotiate in good faith reasonable and customary
Development charges that may apply. Any such Product shall be subject to the Per-Unit Fee set forth in Section 3.1(a). 

(b)    In the event scPharma desires exclusivity for such Product and/or in an Additional Field, scPharma will notify
Sensile in writing the scope of the desired exclusivity (such notice, the “Additional Field Notice”), Such exclusivity may be defined by the applicable Drug, the Drug class, the intended use, or a therapeutic area. If such
exclusivity is requested by scPharma, scPharma’s notice will contain certain milestones required to maintain such exclusivity. Such milestones may relate to [***]. Sensile shall respond to such exclusivity request within [***] with acceptance
or denial of the request for exclusivity. In the event Sensile accepts such request by written notice to scPharma (the “Exclusivity Acceptance Notice”), scPharma shall pay Sensile a royalty on Net Sales of such Product as set forth
in Section 3 below. For each Additional Field granted to scPharma exclusively, the Incremental Disposable Units volume established in Exhibit 2.6(a) will be added to the Minimum Volumes. The following example is to clarify
the aggregate minimum volumes: [***]. 
 (c)    In the event scPharma has not requested exclusivity by means of an
Additional Field Notice, Sensile may elect to grant scPharma exclusivity for the class of therapeutic agents to which the Product belongs, in exchange a royalty on Net Sales of such Product as set forth in Section 3 below. 

3.    FEES AND PAYMENT 

3.1    Consideration. 

  
 8 

 (a)    Per-Unit Fee. scPharma
will pay Sensile the per unit prices set forth in Schedule 3.1(a) for each Reusable Component and Disposable Component included in a product sold to a Third Party or used in clinical trials (the “Reusable Component Per-Unit Fee” and “Disposable Component Per-Unit Fee,” respectively, and collectively, the “Per-Unit
Fee”) For avoidance of doubt, no Per-Unit Fee is payable for units used in release testing or for samples. 

(b)    Royalty on Net Sales. scPharma will pay Sensile a [***] royalty on Net Sales of Products. In the event the
exclusivity lapses under Section 2.6 or Sensile materially breaches an obligation (including with respect to scPharma’s ability to maintain exclusivity), then with respect to the countr(y)/(ies) or Product(s) for which scPharma no
longer has exclusivity, all royalty obligations shall immediately cease. 
 3.2    Sales Reports. Within [***] of
the end of each calendar quarter, scPharma shall deliver to Sensile a report setting forth, for such calendar quarter, the following information, on a
Product-by-Product, country-by-country and Territory-wide basis: (a) Net
Sales of each Product, (b) units sold of each Product, (c) the Per-Unit Price due for the sale of Products, (d) the royalty payment due hereunder, and (e) the basis for
any adjustments to the royalty payment or Per-Unit Prices payable for such calendar quarter. The total royalty and Per-Unit Price due for the sale of all such Products
during such calendar quarter shall be remitted [***]. 
 3.3    Royalty Terms. The obligation to pay royalties
under this Agreement shall be imposed only once with respect to any sale of any Product to end users/distributors, and shall not attach with respect to any intra-company transfers between scPharma Affiliates. With respect to any particular Product
in any particular country, scPharma shall only be obligated to pay royalties during the period during which the sale, offer for sale or importation of such Product in such country would infringe, but for the license granted herein, a valid claim in
a Patent Right included in the Sensile Pre-Existing Intellectual Property or Sensile Inventions covering such Product in such country. 

3.4    Payments. Late payments for amounts that are not the subject of a good faith dispute shall accrue interest
[***]. All payments due hereunder to Sensile shall be made in United States Dollars, and are exclusive of all sales, use, value added, withholding and other taxes and duties. Payments will be made via wire transfer to the account specified by
Sensile in writing from time to time, 
 3.5    Books and Records. scPharma shall keep books and accounts of
record in connection with the sale of Products in sufficient detail to permit accurate determination of all figures necessary for verification of royalties to be paid hereunder. scPharma shall maintain such records for a period of [***] after the
end of the calendar quarter in which they were generated. All reports and financial information of scPharma shall be deemed to be scPharma’s Confidential Information and subject to the provisions of Section 4. 

3.6    Audit Right. Upon [***] prior written notice, a public accounting firm engaged by Sensile and to which
scPharma has no reasonable objection shall have the right to inspect the books of account, records, documents and instruments of scPharma related to the sales of Products [***], at any time during regular business hours during the term of this
Agreement to ascertain the accuracy of such records; provided, however, that such audits may not be performed by Sensile more than once per calendar year and that Sensile shall not be permitted to audit the same period of time more
than once. Such accountant, prior to any 

  
 9 

 
review hereunder, shall have entered into an appropriate confidentiality agreement with scPharma and shall have been instructed not to reveal to Sensile the details of its review information
presented in a summary fashion as is necessary to report the accountant’s conclusions to Sensile. The calculation of all amounts with respect to each calendar quarter shall be binding and conclusive upon both Parties [***] after the close of
said quarter. [***] 
 4.    CONFIDENTIALITY 

4.1    Confidentiality Obligations. The Receiving Party acknowledges that it will have access to the Disclosing
Party’s Confidential Information. The Receiving Party agrees that it will not (a) use any such Confidential Information in any way, for its own account or the account of any Third Party, except for the exercise of its rights and
performance of its obligations under this Agreement, or (b) disclose any such Confidential Information to any person or entity, other than furnishing such Confidential Information to (i) its employees, contractors and
consultants who are required to have access to the Confidential Information in connection with the exercise of Receiving Party’s rights or performance of its obligations under this Agreement and (ii) its accountants and advisors who
have a “need-to-know” for the purpose of providing services to such Party; provided, however, any and all of the above-described
employees, contractors, consultants and advisers are bound by written agreements or, in the case of attorneys or other professional advisers, formal ethical duties, requiring to treat, hold and maintain such Confidential Information in accordance
with the terms and conditions of this Section 4 or for the purpose of evaluating the applicable investment, loan or acquisition. The Receiving Party agrees that it will not allow any unauthorized person access to the
Disclosing Party’s Confidential Information, and that the Receiving Party will take all action reasonably necessary to protect the confidentiality of such Confidential Information, including implementing and enforcing procedures to minimize the
possibility of unauthorized use or copying of such Confidential Information. 
 4.2    Disclosures Required by
Law. In the event the disclosure of the Disclosing Party’s Confidential Information is required by applicable law, judicial or regulatory subpoena, Receiving Party shall provide Disclosing Party with prompt written notice of any such
requirement in order to afford Disclosing Party time either to seek an appropriate protective order (or other remedy) or a waiver of compliance therewith. If such order or other remedy is not obtained, Receiving Party shall disclose only that
portion of the applicable Confidential Information that, in the opinion of counsel to such Party, is legally required to be disclosed and shall exercise all reasonable efforts to obtain assurances that confidential treatment will be accorded the
applicable information. Receiving Party shall cooperate reasonably with Disclosing Party in all respects in seeking to obtain a protective order or other remedy or otherwise to diligently contest or limit the required disclosure. 

4.3    Terms of this Agreement. 

(a)    Confidentiality. Neither Party will disclose any of the terms of this Agreement to any Third Party without
the prior written consent of the other Party. Notwithstanding the foregoing, either Party may disclose such terms: 

(i)    to (A) its accountants and advisors who have a “need-to-know” for the purpose of providing services to such Party and (B) existing and potential investors, lenders, acquirers, collaboration and/or
co-development partners, distributors, reseller, licensees and the accountants and advisors of any of the foregoing; provided that any such recipient under either of the foregoing clauses (A) or
(B) is bound by a 

  
 10 

 
written agreement (or in the case of attorneys or other professional advisors, formal ethical duties) requiring such recipient to treat, hold and maintain the terms of this Agreement on a
confidential basis, and 
 (ii)    in order to comply with an applicable judicial process, if in the
reasonable opinion of such Party’s counsel, such disclosure is necessary for such compliance, provided that such Party shall notify the other Party of such Party’s intent to make any such disclosure sufficiently prior to making such
disclosure so as to allow such other Party adequate time to review and comment on such disclosure and further to take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed. 

(b)    Legal and Regulatory Requirements. This Agreement and terms hereof may be disclosed as otherwise
required pursuant to applicable law, regulation, stock market or stock exchange rule or rule of a self-regulatory organization (e.g., rules or regulations of the United States Securities and Exchange Commission, the NASDAQ or the NYSE); provided
that a Party proposing to make such a disclosure as required by law, rule or regulation shall inform the other Party a reasonable time prior to such required disclosure, shall provide the other Party with a copy of the text of such proposed
disclosure sufficiently in advance of the proposed disclosure to afford such other Party a reasonable opportunity to review and comment upon the proposed disclosure (including, if applicable, the redacted version of this Agreement) and shall
reasonably consider, consistent with applicable law, rule and regulation (including interpretations thereof), the requests of the other Party regarding confidential treatment for such disclosure. Without limiting any of the foregoing, the filing
Party shall request confidential treatment of sensitive provisions of the Agreement to the extent permitted by applicable laws and as reasonably practicable. 

5.    REPRESENTATIONS, WARRANTIES AND COVENANTS 

5.1    Authority. Each Party represents, warrants and covenants to the other Party that (a) it has all
requisite power and authority (corporate and otherwise) to enter into this Agreement and this Agreement has been duly and validly executed and delivered by it; (b) all necessary consents, approvals and authorizations of all government
authorities and other persons required will be obtained by the Effective Date in connection with the execution, delivery and performance of this Agreement; (c) its execution and delivery of this Agreement and the performance of its
obligations hereunder do not and will not conflict with, or result in a breach of, or a default under, its organizational instruments or any other agreement, instrument, order, or law applicable to it or by which it may be bound. 

5.2    Intellectual Property. Sensile represents, wan-ants and covenants to
scPharma that, with respect to any Intellectual Property subject to this Agreement, (a) there is no claim, suit, proceeding, or other investigation pending, nor to the actual knowledge of such Party, overtly threatened, which is likely
to prevent or materially interfere with such Party’s timely performance under this Agreement, (b) it is the sole and exclusive owner of the Sensile Pre-Existing Intellectual Property and Sensile
Inventions, all of which is free and clear of any claims, liens, charges or encumbrances, (c) it has the right to grant the licenses granted herein, and this Agreement, including the grant of the licenses herein, shall not violate or breach any
other existing obligation of Sensile to any Third Party. Sensile represents, warrants and covenants to scPharma that, to the best of its knowledge, the Sensile Pre-Existing Intellectual Property and Sensile
Inventions are subsisting, valid and enforceable in each jurisdiction in which presently pending. Sensile’s employees and subcontractors have executed, or will 

  
 11 

 
execute, prior to performing any activities under the Development Plan or otherwise performing services contemplated by or exercising rights or fulfilling obligations on behalf of Sensile under
this Agreement, written intellectual property assignment and confidentiality and nondisclosure agreements sufficient to enable each Party to exercise its respective rights and comply with its respective intellectual property and confidentiality
obligations under this Agreement. In particular, Sensile Patent AG represents and warrants that it owns the rights, title, and interest in the Sensile Pre-Existing Intellectual Property and Sensile Inventions
based on each inventor either (A) having been an employee of Sensile Medical AG at the time of conception and production of the invention disclosed and/or claimed in the one or more Licensed Patents on the basis that the invention was made in
the course of their work for Sensile Medical AG and in performance of their contractual obligations, and Sensile Medical AG having then assigned all rights, title, and interest in the Licensed Patents to Sensile Patent AG via a valid assignment
agreement, or (B) or having assigned all rights, title, and interests of the one or more Licensed Patents on which that inventor is named to Ecole Polytechnique Federale De Lausanne (EPFL) of Lausanne, Switzerland, and EPFL having then
assigned all rights, title, and interest in the Licensed Patents to Sensile Patent AG via a valid assignment agreement. 

5.3    Third Party Licenses. Without limitation to any other representation, warranty or covenant, Sensile
represents, warrants and covenants that, as needed and reasonably feasible, Sensile shall seek out a license, at no cost to scPharma, to ensure the unencumbered use of the Device by scPharma. 

5.4    Disclaimer. EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR
IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE. NEITHER PARTY WARRANTS THAT THE RESULTS OF THE DEVELOPMENT ACTIVITIES OR THE DEVICE WILL BE
IN ACCORDANCE WITH THE EXPECTATIONS OF THE OTHER PARTY OR WILL PRODUCE OR RESULT IN THE DESIRED END PRODUCT, THAT THE DEVICE WILL BE SAFE, EFFECTIVE, OR COMMERCIALLY VIABLE, OR THAT THE DEVICE WILL BE APPROVED BY ANY REGULATORY AUTHORITY. THE
FOREGOING DISCLAIMER SHALL APPLY EVEN IF A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH WARRANTY, AND NOTWITHSTANDING THE FAILURE OF THE ESSENTIAL PURPOSE OF SUCH WARRANTY. 

6.    OWNERSHIP OF INVENTIONS AND INTELLECTUAL PROPERTY RIGHTS 

6.1    Ownership. 

(a)    Inventions. Each Party’s ownership of Pre-Existing
Intellectual Property is not affected by this Agreement, and neither Party shall have any claims to or rights in any Pre-existing Intellectual Property of the other Party, except as expressly provided for in this Section 6. Sensile shall
be the sole owner of Sensile Inventions, and scPharma shall be the sole owner of scPharma Inventions, The Parties agree to promptly and fully disclose any and all scPharma Inventions and Sensile Inventions to each other in writing. To the extent
scPharma has any rights in Sensile Inventions, scPharma hereby assigns and agrees to assign to Sensile all of its Intellectual Property and proprietary rights, title and interest in and to Sensile Inventions; and all rights of action and claims for
damages and benefits arising due to past and present infringement of said rights. To the extent Sensile has any rights in the scPharma Inventions, Sensile hereby assigns and agrees to assign to scPharma all of its Intellectual Property and
proprietary rights, title and interest in and to the scPharma Inventions; and all rights of action and claims for damages and benefits arising due to past and present infringement of said rights. 

  
 12 

 (b)    Clinical Trial Results. With the exception of Sensile
Inventions in the Clinical Trial Results (defined below), notwithstanding anything to the contrary in any of the Original Agreements, to the extent allowable under applicable law, scPharma shall own all right, title and interest in and to the data,
results, discoveries, material, methods, processes, knowledge, know-how, experience, patentable or non-patentable inventions, technology and information of any type whatsoever arising from, or discovered or reduced to practice within the framework
of, conducting a Clinical Trial (“Clinical Trial Results”). “Clinical Trial Results” further means any and all tangible forms, which embody or contain the Clinical Trial Results. The Clinical Trial Results shall deemed to
be Confidential Information proprietary to scPharma. Notwithstanding anything to the contrary in any of the Original Agreements, scPharma shall have no obligation to share any portion of the Clinical Trial Results with Sensile Med or Sensile
Holding. For the avoidance of doubt, Sensile shall have1 no right, title or interest in or to the Clinical Trial Results. 

(c)    Molds, Tools and Equipment. Notwithstanding anything to the contrary in the Original Agreements, scPharma
shall be the owner of all molds, tools, and equipment designed specifically for the making of each Device. 

(d)    Molds, tools, and equipment related to the manufacturing of the SenseCore pump components (Pump shaft and Pump
housing) shall not be changed or modified without the explicit consent of Sensile, which consent shall not be unreasonably withheld, delayed or conditioned. 

(e)    Use of Devices in Marketing. Prototypes, Devices and Device components developed under this Agreements for
scPharma may be of value to Sensile in its marketing and business development activities with third parties outside the Exclusive Field. Subject to availability after meeting customer demand, Sensile may request from scPharma permission for the use
of up to [***] selected from Prototypes, Devices, and Device components (“Marketing Devices”) for its marketing and business development purposes outside the Exclusive Field, which permission will not be unreasonably withheld,
delayed or conditioned. Sensile may not sell Marketing Devices for commercial purposes in any field. All use of Marketing Devices shall be subject to scPharma’s Intellectual Property rights and ownership of molds, specifications, drawings, and
blueprints for the Device. For avoidance of doubt, Sensile shall not have the right, and shall not communicate to others that it has the right, to utilize scPharma’s molds, specifications, drawings or blueprints, or scPharma’s Intellectual
Property Rights, to manufacture the Device or Product for a Third Party, in any field. Sensile may disclose to Third Parties design drawings and the identify of materials used, but no other information regarding the Product or Device or any
component thereof. Sensile will pay scPharma the same PER-UNIT FEES, in addition to applying the production costs per device, as described in SCHEDULE 3.1(a) to this agreement for all Marketing
Devices 
 6.2    Prosecution. 

(a)    Sensile shall have the sole right to file, prosecute, and maintain Patent Rights with respect to Sensile’s Pre-Existing Intellectual Property and Sensile Inventions, and all costs and expenses associated therewith shall be borne by Sensile. scPharma shall have the sole right to file, prosecute, and maintain Patent Rights
with respect to scPharma’s Pre-Existing Intellectual Property and scPharma Inventions, and all costs and expenses 

  
 13 

 
associated therewith shall be borne by scPharma. Each Party agrees to cooperate and assist the other Parry to execute, and shall cause its personnel to execute, all documents reasonably necessary
for the other Party to secure, perfect, effectuate and preserve such Party’s ownership rights in and to their respective inventions. Sensile shall consult with and keep scPharma informed of all substantive issues relating to the preparation,
filing, prosecution and maintenance of the Sensile Pre-Existing Intellectual Property and Sensile Inventions, and shall furnish to scPharma copies of documents relevant to such preparation, filing, prosecution
or maintenance in sufficient time prior to filing such document to allow for review and comment by scPharma. Sensile shall consider scPharma’s comments in good faith and, to the extent possible in the reasonable exercise of its discretion,
shall incorporate all such comments. In the event that Sensile does not incorporate any such comment, it shall contact scPharma to discuss and resolve any disagreement thereto in good faith. 

(b)    Sensile shall not file any application for a Patent Right that claims or Covers a combination of Sensile’s Pre-Existing Intellectual Property or Sensile Inventions with a pharmaceutical product related to a Drug in the Field of Use or in a field for which scPharma has sent an Additional Field Notice for any existing and
agreed upon future Products (“Combination Intellectual Property”). 
 (c)    scPharma shall not file
any application for a Patent Right that claims or Covers Sensile Pre-Existing Intellectual Property or Sensile Inventions without prior approval by Sensile, which shall not be unreasonably withheld,
conditioned or delayed. Notwithstanding, this Section 6.2(c) shall not prevent scPharma from filing any Patent Right application that claims or Covers a drug-device combination. In the event that, after the Effective Date,
(i) scPharma files a Patent Right application that claims or covers a drug-device combination, and (ii) a Patent Right issues to scPharma from such Patent Right application that, absent a license from scPharma, would prevent
Sensile from making, using, selling or offering for sale any Sensile Pre-Existing Intellectual Property or Sensile Inventions, then scPharma shall grant Sensile a perpetual, royalty-free license under such
Patent Right solely to the extent that such a license is required to make, use, sell, offer to sell and import Devices and only in the Excluded Field for such country where such patent was issued. For purposes of clarity, such license shall not
extend to the Field of Use or any therapeutic area or field where scPharma has exclusivity to the Sensile Pre-Existing Intellectual Property or Sensile Inventions. 

(d)    During the term of this Agreement, Sensile and its Affiliates will not disclose the Device Master Record
(“DMR”) to any Third Party without permission of scPharma. 
 6.3    Enforcement. 

(a)    As between scPharma and Sensile, Sensile has the first right to take legal action to prevent or abate any actual
or threatened misappropriation or infringement (each an “Infringement Action”) and attempt to resolve any claims directly relating to the Sensile Pre-Existing Intellectual Property or Sensile Inventions. Each of the Parties shall
notify the other Party within [***] if they become aware of any such Infringement Action. In the event Sensile does not wish to take any such legal action or abatement, Sensile shall promptly, but in no event more than [***] after becoming aware of
such misappropriation or infringement, notify scPharma and scPharma shall thereafter have the right to take and control legal action against such infringement or misappropriation. The Party commencing legal action (the “Defending
Party”) shall, unless otherwise agreed in writing, bear its own costs and expenses in such proceedings and have the right to control the conduct thereof and be represented by counsel of its choice. The Defending Party shall consider in good
faith requests and comments by the other Party. 
 (b)    Each Party will cooperate in all reasonable respects with the
Defending Party. The Defending Party may prosecute or defend an Infringement Action in its own name or, if required by applicable law, in the name of another Party and may join such other Party as a party to the Infringement Action if a court of
competent jurisdiction determines that such Party is an indispensable party to such Infringement Action, in each case, at the cost of the Defending Party. Each Party hereby irrevocably and unconditionally waives any objection to such joinder,
including on 

  
 14 

 
grounds of personal jurisdiction, venue or forum non conveniens. Where the Defending Party brings an Infringement Action in the name of another Party or joins another Party, the Defending Party
may not settle those proceedings or agree to any order, injunction, settlement or other binding obligation that prohibits or restricts that named or joined Party in any way without the prior written consent of that named or joined Party. 

(c)    Any proceeds received from an Infringement Action shall first be applied to reimburse legal fees of the respective
Parties in proportion to the costs and expenses incurred. Any such proceeds exceeding the sum of the Parties’ legal fees shall be allocated between the parties in the following proportions (which correspond to the proportion of Net Sales to
which each Party is entitled): scPharma shall have the right to receive [***] of any such excess proceeds and Sensile shall have the right to receive [***] of such excess proceeds. 

7.    TECHNOLOGY ESCROW 

7.1    Within [***] of the date of signing this Agreement, the parties shall enter into a technology escrow agreement
(“Escrow Agreement”) with a mutually acceptable escrow agent (“Escrow Agent”). Within [***] of the execution of said Escrow Agreement, Sensile shall deposit with the Escrow Agent: (a) executed
authorization letters in the form set forth in Exhibit 7.1 for each subcontractor and vendor it uses in the manufacture or design of the Device, (b) a copy of the design history file for each Device, (c) a copy of
the device master record for each Device, (d) specifications for each Device, and (e) designs for molds, tools, and any other equipment designed specifically for the manufacture of a Device or any component thereof (the
“Deposit”). Sensile shall update the Deposit on [***] basis, and shall deposit additional authorization letters each time it engages a new subcontractor or vendor, and each time an existing subcontractor or vendor begins work on a
new Device. Sensile shall retain, or cause its subcontractors or vendors to retain, a copy of all documents included in the Deposit for its records. The Escrow Agreement shall instruct the Escrow Agent to: (1) not return the Deposit, or
any part thereof to Sensile, without obtaining the prior written consent of scPharma; (ii) designate scPharma as the sole and exclusive beneficiary, along with any successors or assigns of scPharma, as confirmed in writing by scPharma,
and (iii) notify scPharma when deposits have been received. scPharma shall pay all costs and fees associated with the escrow account when due and payable. The following events shall constitute a release event under the Escrow Agreement
and shall immediately entitle scPharma to request from the Escrow Agent, and the Escrow Agent to release to scPharma, the Deposit: (i) Sensile notifies Escrow Agent to release the Deposit to scPharma; (ii) Sensile materially
breaches this Agreement and fails to cure such breach; (iii) Sensile notifies scPharma that it no longer has the capacity to make Devices; (iv) Sensile has been unable to meet its supply obligations for [***];
(v) Termination for Insolvency of Sensile; or (vi) or Sensile commits more than [***] of a material obligation in a period of [***] (each, a “Release Event”). In the event of a Release Event, scPharma shall
promptly notify the Escrow Agent to release the Deposit and Sensile shall execute all documents and provide all assistance required for the Escrow Agent to effect such release, promptly after requested to do so. Sensile shall not enter into any
definitive agreement with an Escrow Agent regarding the Deposit without prior review and written approval of the execution version of such agreement by scPharma. 

7.2    Sensile shall ensure that any subcontractor or vendor it uses under this Agreement (or generally in the manufacture
or design of the Device): (a) shall be obligated to assist in any technology transfers contemplated in this Agreement in the manner set forth herein, (b) shall timely effect such technology transfers, and (c) shall accept the
assignment of such subcontractor’s or vendor’s contract to scPharma upon any transfer authorized by the parties’ agreements. For the avoidance of doubt, scPharma shall continue to be obligated to pay royalties per the terms of this
Agreement (and subject to the termination provisions of such agreement) following a Release Event. 

  
 15 

 8.    INDEMNIFICATION 

8.1    Indemnification by Sensile. Sensile shall defend, indemnify, and hold harmless scPharma, its Affiliates and
their respective officers, directors, employees, and agents (“Representatives”) from and against any and all claims, losses, demands, causes of action, and all related costs and expenses of every kind (including reasonable
attorneys’ fees, costs, and expenses) occurring, growing out of, incident to, or resulting directly or indirectly from a Third Party claim based on: (a) Sensile’s fraud, willful or intentional acts or gross negligence;
(b) Sensile’s grossly negligent design or manufacture of products; (c) infringement of an Intellectual Property Right of a Third Party resulting from product design, features, or manufacturing processes developed by
Sensile; (d) Sensile’s breach of a material obligation under this Agreement; and (e) Sensile’s failure to comply with applicable laws, in each case except for those losses for which scPharma has an obligation to
indemnify Sensile, as to which losses each Party will indemnify the other to the extent of their respective liability for the losses. 

8.2    Indemnification by scPharma. Except as otherwise provided in Section 8.1 above, scPharma
shall defend, indemnify, and hold harmless Sensile, its Affiliates and their respective Representatives from and against any and all claims, losses, demands, causes of action, and all related costs and expenses of every kind (including reasonable
attorneys’ fees, costs, and expenses) occurring, growing out of, incident to, or resulting directly or indirectly from a Third Party claim based on: (a) scPharma’s fraud, willful or intentional acts or gross negligence;
(b) scPharma’s breach of a material obligation under this Agreement; and (c) scPharma’s failure to comply with applicable laws, in each case except for those losses for which Sensile has an obligation to indemnify
scPharma, as to which losses each Party will indemnify the other to the extent of their respective liability for the losses. 

8.3    Conditions of Indemnity. 

(a)    The Parry claiming a right of indemnification or defense under this Agreement shall provide the indemnifying Party
prompt written notice (in all events within [***] of any such claim, including a copy thereof, served upon it, and shall cooperate fully with the indemnifying Party and its legal representatives in the investigation of any such claim, at the
indemnifying Party’s expense. 
 (b)    The indemnifying Party shall have the right to exercise sole control over
the defense and settlement of any such claim, including the sole right to select defense counsel and to direct the defense or settlement of any such claim; provided that the indemnifying Party shall not enter into any
non-monetary settlement or admit fault or liability on the indemnified Parry’s behalf without the prior written consent of the indemnified Party, which consent shall not be unreasonably withheld, delayed
or conditioned. Notwithstanding the foregoing, if the indemnified Party is advised by counsel that there may be a conflict between the positions of the indemnifying Party and the indemnified Party in conducting the defense of such action, then the
indemnified Party may elect to conduct the defense to the extent reasonably determined by such counsel to be necessary to protect the interests of the indemnified Party, at the expense of the Indemnifying Party, if it is determined by agreement of
the indemnifying Party and the indemnified Party, or by a court of competent jurisdiction, that the indemnified Party is entitled to indemnification hereunder. If the indemnifying Party elects not to assume the defense of such claim or action, the
indemnifying Party shall reimburse the indemnified Party for the reasonable legal fees and expenses incurred and shall be bound by the results obtained by the indemnified Party in respect of such claim or action if it is determined by agreement of
the indemnifying Party and the indemnified Party or by a court of competent 

  
 16 

 
jurisdiction that the indemnified Party is entitled to indemnification hereunder; provided, however, that no such claim or action shall be settled without the written consent of the indemnifying
Party. Without limiting the foregoing, the indemnified Party shall have the right to select and to obtain representation by separate legal counsel, and except as provided for above, all costs and expenses incurred by the indemnified Party for such
separate legal counsel shall be borne by the indemnified Party. 
 (c)    Either Party shall be relieved of any
indemnification obligation hereunder if the indemnified Party either [***]. 
 9.    LIMITATION OF LIABILITY 

EXCEPT FOR LIABILITY FOR A BREACH OF [***] OR A BREACH OF [***] OR [***] AND EACH PARTY’S INDEMNITY OBLIGATIONS FOR
CLAIMS ASSERTED BY THIRD PARTIES, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ITS AFFILIATES FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL DAMAGES, INCLUDING ANY CLAIMS FOR DAMAGES BASED UPON LOST PROFITS RELATING TO THIS AGREEMENT, EVEN IF
SUCH PARTY HAS BEEN INFORMED IN ADVANCE OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT FOR LIABILITY FOR A BREACH OF [***] OR A BREACH OF [***] OR [***] AND EACH PARTY’S INDEMNITY OBLIGATIONS FOR CLAIMS ASSERTED BY THIRD
PARTIES, EACH PARTY’S AGGREGATE LIABILITY TO THE OTHER PARTY FOR ANY CLAIM RELATED TO, OR IN CONNECTION WITH, THIS AGREEMENT, OR THE PRODUCT (WHETHER TN CONTRACT, TORT, NEGLIGENCE, STRICT LIABILITY, BY STATUTE OR OTHERWISE) SHALL BE LIMITED TO
AN AMOUNT EQUAL TO THE TOTAL PAYMENTS BY SCPHARMA TO SENSILE UNDER THIS AGREEMENT. 
 In no event shall a party’s liability to the
other party for direct or indirect damages exceed $[***] for a single event or aggregate related events (aggregate event limit). 

10.    TERM AND TERMINATION 

10.1    Term. This Agreement shall commence on the Effective Date and extend until terminated as set forth in this
Agreement (the “Term”). 
 10.2    Termination for Business Reasons. This Agreement may be
terminated for any reason by scPharma, including scPharma’s decision not to continue development of a Product or failure of a Product to receive approval from the appropriate Regulatory Authority, upon sixty (60) days prior written notice
to Sensile, Upon receipt of notice of termination from scPharma, Sensile shall use its best efforts to limit or terminate any outstanding financial commitments for which scPharma will be held responsible within [***] of termination by scPharma. For
any termination pursuant to this Section 10.2, scPharma shall reimburse Sensile for all costs incurred by it for work performed by Sensile prior to the effective date, of termination, including all
non-cancellable obligations. Payments under this Section 10.2 shall be subject to Section 2 hereof. 

10.3    Termination for Material Breach. Either Party shall have the right to terminate this Agreement upon written
notice to the other Party if, after receiving written notice of such material breach, the other Party fails to cure such breach within ninety (90) days from the date of such notice. 

  
 17 

 10.4    Termination for Insolvency. A Party may terminate this
Agreement upon bankruptcy, insolvency, dissolution or winding up of the other Party (“Termination for Insolvency”). 

(a)    In the event of Termination for Insolvency of Sensile, (i) the applicable escrow agent will release to
scPharma the authorization letters and other deposits made in accordance with the Escrow Agreement and (ii) Sensile shall, upon request by scPharma, transfer to scPharma or cause to transfer to scPharma all works in progress, completed
Devices and components thereof, all Sensile Pre-Existing Intellectual Property and Sensile Inventions necessary for scPharma to continue to manufacture the Products in according with the applicable specifications. If this Agreement is terminated
under any applicable insolvency law or Sensile or an administrator refuses to further perform this Agreement (or any of Sensile’s obligations hereunder) under any applicable bankruptcy or insolvency law, then scPharma may elect to retain all of
its license rights under this Agreement (including the rights described in this Section 10.4). All rights and licenses granted under or pursuant to this Agreement by ether Party are, and shall otherwise be deemed to be, for purposes of
Section 365(n) of the United States Bankruptcy Code (the “Bankruptcy Code”), licenses of rights to “intellectual property” as defined under Section 101 of the Bankruptcy Code. The Parties agree that
the scPharma, as licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code. 

(b)    In the event of Termination for Insolvency of scPharma, all obligations of Sensile to scPharma under this
Agreement, including any licenses granted by Sensile to scPharma shall immediately terminate. scPharma shall reimburse Sensile for all costs incurred by it for work performed by Sensile prior to the effective date of termination, including all non-cancellable obligations. 
 10.5    Rights and Duties Upon Termination.
Upon termination of the Agreement, Sensile and scPharma will cooperate to provide for an orderly termination of the Development Plan. Upon notice of termination of this Agreement, the Parties agree to use reasonable efforts to minimize further
costs. Each Party shall also promptly return all Confidential Information of the other Party in its custody or control. Termination of this Agreement shall not affect any other rights or remedies which may be available to either Party at law or in
equity. 
 10.6    Survival of Provisions. In addition to any provisions that by their nature survive expiration
or termination of this Agreement, the duty of scPharma to pay accrued but unpaid fees and Sections 1 (Definitions), 3.5 (Books and Records), 4 (Confidentiality), 5 (Representations, Warranties and Covenants),
6.1 (Ownership of Inventions, 8 (Indemnification), 9 (Limitation of Liability), 10.5 (Rights and Duties upon Termination), 10.6 (Survival of Provisions) and 11 (Miscellaneous) shall survive the
termination or expiration of this Agreement for any reason. Section 7.1 shall survive termination for Insolvency of Sensile or termination for Sensile’s material breach, for so long as is necessary for the Escrow Agent to receive
instructions and complete the release following a Release Event. For the purpose of clarification, the following sections will not survive the termination of this agreement: Section 2 (License), except pursuant to
Section 10.4(a). 
 11.    MISCELLANEOUS 

11.1    Independent Contractors. The relationship between Sensile and scPharma is that of independent contractors
and nothing herein shall be deemed to constitute 

  
 18 

 
the relationship of partners, joint venturers, or principal and agent between Sensile and scPharma. Neither Party shall have any express or implied right or authority to assume or create any
obligations on behalf of or in the name of the other Party or to bind the other Party to any contract, agreement, or undertaking with any Third Party. 

11.2    Assignment; Subcontracting. scPharma may assign this Agreement, or assign or delegate any rights or
obligations under this Agreement, without Sensile’s consent. Sensile may not assign this Agreement, or assign or delegate its rights or obligations under this Agreement, without the prior written consent of scPharma (which shall not be
unreasonably withheld, conditioned, or delayed), provided, however, that (a) Sensile may assign this Agreement without the prior written consent of scPharma to an Affiliate or in the event of a sale of all or substantially all of such
Party’s assets or business. Any permitted assignee shall assume all obligations of its assignor under this Agreement. No assignment shall relieve either Party of its responsibility for the performance of any obligation that accrued prior to the
effective date of such assignment. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective permitted successors and assigns. Any attempted sale, pledge, assignment, sublicense or other transfer in
violation of this Section 11.2 shall be void and of no force or effect. 
 11.3    Waiver. No failure
or delay on the part of the Parties hereto to exercise any right, power, or privilege hereunder or under any instrument executed pursuant hereto shall operate as a waiver; nor shall any single or partial exercise of any right, power or privilege
preclude any other or further exercise thereof or the exercise of any other right, power or privilege, 

11.4    Severability. If any provision or part of this Agreement is declared invalid by any court of competent
jurisdiction or a government agency having jurisdiction, such invalidity shall not affect the remainder of the provision or the other provisions of the Agreement, which shall remain in full force and effect. 

11.5    Publication; Use of Name. Neither Party shall issue any press release, publicity or other form of public
written disclosure related to this Agreement, the activities conducted hereunder, or the other Party without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned, or delayed. Except as otherwise
required by, or in the good faith determination by a Party, complies with, Law or securities disclosure rules or guidance, or as required by the terms of this Agreement or mutually agreed upon by the Parties, neither Party shall make any use of the
name of the other Party in any advertising or promotional material, or otherwise, without the prior written consent of the other Party. 

11.6    Further Assurances. Each Party agrees to duly execute and deliver, or cause to be duly executed and
delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in
connection with this Agreement or to carry out more effectively the provisions and purposes, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

11.7    Construction. Unless the context otherwise requires, (a) “or” is not exclusive,
(b) words in the singular include the plural, and words in the plural include the singular, (c) “herein,” “hereof and other words of similar import refer to this Agreement, and

  
 19 

 
(d) “including” and “includes,” when following any general provision, sentence, clause, statement, term or matter, shall be deemed to be followed by % but not limited
to,” and “, but is not limited to,” respectively. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any
ambiguity in this Agreement shall be construed against the drafter shall not apply. 
 11.8    Non-Solicitation. During the term of this Agreement and for a period of [***] thereafter, scPharma shall not, and shall require that its Affiliates do not, directly or indirectly solicit, engage or hire any
employee or contractor of Sensile or its Affiliates; provided, however, that nothing herein shall prohibit scPharma from soliciting for employment, hiring or employing any person who responds to a general solicitation or advertisement in a
newspaper, on the internet, or in some similar medium so long as such general solicitation or advertisement is not directed at any individual employee or group of employees of Sensile or its Affiliates. 

11.9    Notices. Any notices under this Agreement shall be in writing as registered mail and delivered to the
Parties at the postal addresses set forth below, or to the postal address subsequently provided by a Party in accordance with this Section 11.9, by (a) first class certified mail, return receipt requested, with notice deemed given
upon receipt; (b) a nationally-recognized overnight courier service, with notice deemed given on the date of receipt as indicated on the courier’s receipt, or (c) pdf via electronic mail: 

 

			
	if to scPharma:	  	scPharmaceuticals Inc.
		  	131 Hartwell Avenue, Suite 215
		  	Lexington, MA 02421
		  	Attention: [***]
		  	Tel: [***]
		  	Fax [***]
		  	Email address:
		
	if to Sensile:	  	Sensile Medical AG
		  	Fabrikstrasse 10
		  	CH-4614 Hägendorf
		  	Switzerland
		  	Attention: CEO
		  	Tel: [***]
		  	Fax: [***]
		  	Email address:

 The address and person provided above may be changed by either Party by providing the other Party with written notice of such
change. 
 11.10    Counterparts. This Agreement and any amendment or supplement hereto may be executed in
separate counterparts, including by facsimile or electronic signature, each of which shall be deemed to be an original, and all of which taken together shall constitute one and the same instrument. 

11.11    Dispute Resolution; Governing Law. In the event of any controversy or claim arising out of or relating to
this Agreement, or a breach thereof, the Parties hereto shall consult and negotiate with each other and, recognizing their mutual interests, attempt to reach a satisfactory solution. If they do not reach settlement within a period of [***], then,
upon notice by 

  
 20 

 
any party to the other(s), any unresolved controversy or claim shall be settled by arbitration administered by the International Centre for Dispute Resolution (“ICDR”) in accordance
with the provisions of its International Arbitration Rules. The arbitration will be heard and determined by three (3) arbitrators who are retired judges or attorneys with at least seven (7) years of experience in the medical device
industry. Each Party will appoint one (1) arbitrator and the third arbitrator will be selected by the two (2) Party-appointed arbitrators, or, failing agreement within [***] following the date of receipt by the respondent of the claim, by
ICDR. The place of arbitration shall be London, England. The language of the arbitration shall be English. Except as may be required by law, neither a Party nor its representatives may disclose the existence, content, or results of any arbitration
hereunder without the prior written consent of the Parties. The arbitration award so given will be a final and binding determination of the dispute, will be fully enforceable in any court of competent jurisdiction, and will not include any damages
expressly prohibited by Section 9. Except in a proceeding to enforce the results of the arbitration or as otherwise required by law, neither Party nor any arbitrator may disclose the existence, content or results of any arbitration
hereunder without the prior written agreement of both Parties. Notwithstanding the dispute resolution procedures set forth in this Section 11.11, each Party acknowledges and agrees that breach of any of the terms or conditions of this
Agreement would cause irreparable harm and damage to the other and that such damage may not be ascertainable in money damages and that as a result thereof the non-breaching Party would be entitled to seek from
a court equitable or injunctive relief restraining any breach or future violation of the terms contained herein by the breaching Party without the necessity of proving actual damages or posting bond. Such right to equitable relief is in addition to
whatever remedies either Party may be entitled to as a matter of law or equity, including money damages. This Agreement shall be governed by and interpreted in accordance with the laws of England. 

11.12    Entire Agreement. This Agreement and the Original Agreements constitute the entire understanding of the
Parties in connection with the subject matter herein and a complete and exclusive statement of the terms of their agreement and supersede all prior and contemporaneous arrangements, agreements and understandings, both oral and written among the
Parties hereto or between any of them, including the Original Agreements. In the event of any conflict between this Agreement and the Original Agreements or any other previously executed agreement involving the parties hereto, this Agreement shall
control. This Agreement or any provision hereof shall not be amended, supplemented, or waived except in a writing signed by each of the Parties hereto. For purpose of clarification, if subjects are not defined or covered in this agreement, previous
agreements, such as the Partnership Agreement and the Omnibus Amendment are still valid. 
 [Remainder of the page intentionally left
blank] 

  
 21 

 IN WITNESS WHEREOF, this Agreement has been executed by the duly authorized
representatives of the Parties hereto as of the Effective Date. 
  

					
	scPHARMACEUTICALS INC.	  		  	SENSILE HOLDING AG
			
	 /s/ Pieter Muntendam
	  		  	 /s/ Benno Zehnder

	Signature	  		  	Signature
			
	 Pieter Muntendam
	  		  	 Benno Zehnder

	Name	  		  	Name
			
	 President
	  		  	 Member of the Board

	Title	  		  	Title
			
	SENSILE MEDICAL AG	  		  	SENSILE PATENT AG
			
	 /s/ Derek Brandt
	  		  	 /s/ E. Conradi

	Signature	  		  	Signature
			
	 Derek Brandt
	  		  	 E. Conradi

	 Name
	  		  	 Name

			
	 CEO
	  		  	 Chairman of the Board

	Title	  		  	Title

  
 22 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 
 SCHEDULE 1.1 

SENSILE INVENTIONS 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 
 SCHEDULE 1.2 

SENSILE PRE-EXISTING INTELLECTUAL PROPERTY 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

 EXHIBIT 2.6(a) 

Minimum Device Unit Volumes 
  

																	
	 Minimum Volume Calculation
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 Minimum Disposable Units
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 Incremental Disposable Units Per Additional Field
	  		  		  		  		  		  		  		  	
	 following Regulatory Approval
	  	[***]	  	[***]	  	[***]	  		  		  		  		  	
	 Incremental Disposable Units
	  	[***]	  	[***]	  	[***]	  		  		  		  		  	

 SCHEDULE 3.1(a) 

PER-UNIT FEES 

REUSABLE COMPONENT PER-UNIT FEES 

[***] per unit 
 DISPOSABLE COMPONENT PER-UNIT FEES 
 [***] per unit 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

FIRST AMENDMENT TO LICENSE AGREEMENT 

This FIRST AMENDMENT TO LICENSE AGREEMENT (this “First Amendment”) is made and entered into this day of June 29,
2016 (the “First Amendment Effective Date”) by and among scPharmaceuticals Inc., having an address at 131 Hartwell Avenue, Suite 215, Lexington, MA 02421 (“scPharma”) and Sensile Medical AG
(“Sensile Med”) and Sensile Pat AG (“Sensile Pat”), both having an address at Fabrikstrasse 10, CH-4614 Hägendorf, Switzerland and Sensile Holding AG (“Sensile
Holding”), having an address at Zugerstrasse 76b, CH-6340, Baar, Switzerland (Sensile Med, Sensile Holding and Sensile Pat together in any combination, “Sensile”) (each of scPharma,
Sensile Med, Sensile Holding and Sensile Pat, a “Party” and, collectively, the “Parties”). All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the License Agreement
(defined below). 
 RECITALS 

WHEREAS, the Parties entered into that certain License Agreement, dated June 29, 2015, (the “License Agreement”)
pursuant to which scPharma licensed certain products owned by Sensile to perform development activities required to commercialize such products; and 

WHEREAS, the Parties wish to amend the License Agreement by modifying the exclusivity provisions, technology escrow and certain other
terms. 
 NOW, THEREFORE, in consideration of the premises and mutual agreements and covenants set forth in this Amendment,
the Parties have agreed as follows: 
 AGREEMENT 

1.1    Section 2.6(a)(i) of the License Agreement is hereby amended by deleting the date
“[***]” and replacing it with “[***]”. 
 1.2    The first sentence in
Section 7.1 is hereby deleted in its entirety and replaced with the following language: 
 “During the term of
this Agreement, either Party may request a technology escrow by notifying the other Party in writing. Within [***] of delivery of such notice, the Parties shall enter into a technology escrow agreement (“Escrow Agreement”) with a
mutually acceptable escrow agent (“Escrow Agent”).” 

1.3    Exhibit 2.6(a) is hereby deleted in its entirety and replaced with the amended
Exhibit 2.6(a) attached hereto. 
 [Signatures follow on next page] 

 IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this First
Amendment to be executed by their respective authorized representatives. 
  

					
	ScPHARMACEUTICALS INC.	 		  	SENSILE HOLDING AG
			
	 /s/ Pieter Muntendam
	 		  	 /s/ E. Conradi

	Signature	 		  	Signature
			
	 Pieter Muntendam
	 		  	 Erwin Conradi

	Name	 		  	Name
			
	 President
	 		  	 President of the Board of Directors

	Title	 		  	Title
			
	SENSILE MEDICAL AG	 		  	SENSILE PAT AG
			
	 /s/ Derek Brandt     /s/ Lars Birkmann
	 		  	 /s/ E. Conradi

	Signature	 		  	Signature
			
	 Derek Brandt     Lars Birkmann
	 		  	 Erwin Conradi

	Name	 		  	Name
			
	 CEO
                 Head BS
	 		  	 President of the Board of Directors

	Title	 		  	Title

 Signature Page to First Amendment 

 EXHIBIT 2.6(a) 

Minimum Disposable Component Unit Volumes (amended) 
  

															
	Minimum Volume Calculation	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
								
	Minimum Disposable Units	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
								
	Incremental Disposable Units per Additional Field	  		  		  		  		  		  		  	
								
	   following Regulatory Approval
	  	[***]	  	[***]	  	[***]	  		  		  		  	
								
	 Incremental Disposable Units
	  	[***]	  	[***]	  	[***]	  		  		  		  	

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

Amendment #2 
 To
License Agreement 
 This Amendment #2 (“Amendment #2”), dated August 5, 2016 (“Amendment Effective
Date”), to the License Agreement dated June 29, 2015 (the “Agreement”), is by and among scPharmaceuticals Inc. (“scPharma”) and Sensile Medical AG, Sensile Holding AG and Sensile Patent AG
(“Sensile”). 
 Unless defined herein, words used in this Amendment #2 as defined terms shall have the same meanings herein
as in the Agreement. 
 RECITALS 

WHEREAS, scPharma and Sensile each desire to amend the terms of the Agreement as described in this Amendment; and 

NOW, THEREFORE, in consideration of the mutual covenants, promises and agreements herein contained, the Parties hereto agree as
follows: 
 1.    Section 6.3 (a). Section 6.3(a) of the Agreement is deleted in its entirety and
replaced with the following amended 6.3(a): 
 “6.3 Enforcement. [***]. Each of the Parties shall notify the other Party within
[***] if they become aware of any such Infringement Action. [***]. The Party commencing legal action (the “Defending Party”) shall, unless otherwise agreed in writing, [***]. The Defending Party shall consider in good faith requests
and comments by the other Party.” 
 2.    Effectiveness of Agreement and Amendment #2. Except as expressly
provided herein, nothing in this Amendment #2 shall be deemed to waive or modify any of the provisions of the Agreement, which otherwise remains in full force and effect. In the event of any conflict between the Agreement and this Amendment #2, this
Amendment #2 shall prevail with respect to the subject matter hereof. 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment #2 as of the Amendment
Effective Date. 
  

									
	scPharmaceuticals Inc.	  		 	Sensile Medical AG
					
	By:	  	 /s/ Pieter Muntendam
	  		 	By:	 	 /s/ E. Conradi /s/ Lars Birkmann

					
	Name:	  	 Pieter Muntendam
	  		 	Name:	 	 E. Conradi Lars Birkmann

					
	Title:	  	 President
	  		 	Title:	 	 Chairman Head of Business Support

					
	Date:	  	 7/29/2016
	  		 	Date:	 	 5/8/2016    5/8/2016

			
	Sensile Patent AG	  		 	Sensile Holding AG
					
	By:	  	 /s/ E. Conradi
	  		 	By:	 	 /s/ E. Conradi

					
	Name:	  	 E. Conradi
	  		 	Name:	 	 E. Conradi

					
	Title:	  	 Chairman
	  		 	Title:	 	 Chairman

					
	Date:	  	 5/8/2016
	  		 	Date:	 	 5/8/2016

  
 2 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

THIRD AMENDMENT TO LICENSE AGREEMENT 

This THIRD AMENDMENT TO LICENSE AGREEMENT (this “Third Amendment”) is made and entered into this 22 day of November,
2016 (the “Third Amendment Effective Date”) by and among scPharmaceuticals Inc., having an address at 131 Hartwell Avenue, Suite 215, Lexington, MA 02421 (“scPharma”) and Sensile Medical AG, having an address at
Fabrikstrasse 10, CH-4614 Hägendorf, Switzerland (“Sensile Med”) and Sensile Holding AG (“Sensile Holding”) and Sensile Patent AG (“Sensile Patent”),
both having an address at Zuger Strasse 76b, CH-6340, Baar, Switzerland (Sensile Med, Sensile Holding and Sensile Patent together in any combination, “Sensile”) (each of scPharma, Sensile Med,
Sensile Holding and Sensile Patent, a “Party” and, collectively, the “Parties”). All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the License Agreement (defined below).

 RECITALS 

WHEREAS, the parties entered into that certain License Agreement dated June 29, 2015, as amended by that First Amendment to
License Agreement dated June 29, 2016 and that Second Amendment to Non-Exclusive License Agreement dated August 5, 2016 (as amended, the “License Agreement”) pursuant to which
scPharma licensed certain products owned by Sensile to perform development activities required to commercialize such products; and 

WHEREAS, the Parties wish to amend the License Agreement by modifying the exclusivity provisions therein. 

NOW, THEREFORE, in consideration of the premises and mutual agreements and covenants set forth in this Amendment, the Parties have
agreed as follows: 
 AGREEMENT 

1.1    Section 2.6(a)(i) of the License Agreement is hereby amended by deleting the date “[***]” and replacing it with
“[***]”. 
 [Signatures follow on next page] 

 IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this Third
Amendment to be executed by their respective authorized representatives. 
  

					
	ScPHARMACEUTICALS INC.	 		 	SENSILE HOLDING AG 
			
	 /s/ Pieter Muntendam
	 		 	 /s/ E. Conradi

	Signature	 		 	Signature
			
	 Pieter Muntendam
	 		 	 Conradi, Erwin

	Name	 		 	Name
			
	 President and CEO
	 		 	 President

	Title	 		 	Title
			
	SENSILE MEDICAL AG 	 		 	SENSILE PATENT AG
			
	 /s/ Derek Brandt
	 		 	 /s/ E. Conradi

	Signature	 		 	Signature
			
	 Derek Brandt
	 		 	 Conradi, Erwin

	Name	 		 	Name
			
	 CEO
	 		 	 President

	 Title
	 		 	Title

 /s/ Sandra de Haan 
 Sandra de
Haan 
 Head BD 

  
 2 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

FOURTH AMENDMENT TO LICENSE AGREEMENT 

This FOURTH AMENDMENT TO LICENSE AGREEMENT (this “Fourth Amendment”) is made and entered into this 25th day of February, 2017 (the “Fourth Amendment Effective Date”) by and among scPharmaceuticals Inc., having an address at 131 Hartwell Avenue, Suite 215, Lexington, MA 02421
(“scPharma’”) and Sensile Medical AG, having an address at Fabrikstrasse 10, CH-4614 Hägendorf, Switzerland (“Sensile Med”) and Sensile Holding AG (“Sensile
Holding”) and Sensile Patent AG (“Sensile Patent”), both having an address at Zuger Strasse 76b, CH-6340, Baar, Switzerland (Sensile Med, Sensile Holding and Sensile Patent together
in any combination, “Sensile”) (each of scPharma, Sensile Med, Sensile Holding and Sensile Patent, a “Party” and, collectively, the “Parties”). All capitalized terms not otherwise defined herein
shall have the meanings ascribed to them in the License Agreement (defined below). 
 RECITALS 

WHEREAS, the Parties entered into that certain License Agreement dated June 29, 2015 as amended by that First Amendment to License
Agreement dated June 29, 2016, that Second Amendment to Non-Exclusive License Agreement dated August 5, 2016 and that Third Amendment to License Agreement dated November 22, 2016 (as amended,
the “License Agreement”) pursuant to which scPharma licensed certain products owned by Sensile to perform development activities required to commercialize such products; and 

WHEREAS, the Parties wish to amend the License Agreement by modifying the terms as set forth herein. 

NOW, THEREFORE, in consideration of the premises and mutual agreements and covenants set forth in this Amendment, the Parties
have agreed as follows: 
 AGREEMENT 

1.1    Section 2.6(a)(i) of the License Agreement is hereby amended by deleting the date
“[***]” and replacing it with “[***]”. 
 1.2    Exhibit 2.6(a) is hereby
deleted in its entirety and replaced with the amended Exhibit 2.6(a) attached hereto. 
 [Signatures follow on next
page] 

 IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this Fourth
Amendment to be executed by their respective authorized representatives. 
  

					
	 ScPHARMACEUTICALS INC.
	 		  	 SENSILE HOLDING AG

			
	 /s/ John Tucker
	 		  	 /s/ E. Conradi

	Signature	 		  	Signature
			
	 John Tucker
	 		  	 Conradi, E.

	Name	 		  	Name
			
	 CEO
	 		  	 President

	Title	 		  	Title
			
	 SENSILE MEDICAL AG
	 		  	 SENSILE PATENT AG

			
	 /s/ Derek Brandt
	 		  	 /s/ E. Conradi

	Signature	 		  	Signature
			
	 Derek Brandt
	 		  	 Conradi, E.

	Name	 		  	Name
			
	 CEO
	 		  	 President

	Title	 		  	Title

 Signature Page to First Amendment 

 EXHIBIT 2.6(a) 

Minimum Disposable Component Unit Volumes (amended) 

Minimum Volume Calculation 

													
	 following Regulatory Approval of furosemide
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 Minimum Disposable Units
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	
	Incremental Disposable Units per Additional Field
	 following Regulatory Approval
	  	[***]	  	[***]	  	[***]	  		  		  	
	 Incremental Disposable Units
	  	[***]	  	[***]	  	[***]	  		  		  	

 For purposes of this Exhibit 2.6(a), “Year 1” means the period beginning on the date
of the applicable Regulatory Approval and ending one (1) year after Regulatory Approval. “Year 2” means the second year after such Regulatory Approval (i.e., the one-year period following
Year 1), “Year 3” means the third year after such Regulatory Approval, and so on.Exhibit

EXECUTIVE EMPLOYMENT AGREEMENT

This Executive Employment Agreement (“Agreement”) is made and entered into effective as of October 18, 2017 (“Effective Date”) by and between Heritage-Crystal Clean, Inc., a Delaware corporation (the “Company”), and Mark DeVita (“Executive”).
Recitals
A.The Company desires to employ Executive, and Executive desires to be employed by the Company.
B.    The Company and Executive desire to enter into an agreement embodying the terms of such employment.
Agreement
NOW, THEREFORE, in consideration of the foregoing and the mutual promises set forth in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Executive agree as follows:
1.    Term.  The Company hereby agrees to employ Executive, and Executive hereby accepts such employment with the Company, in each case, on the terms and conditions set forth herein.  Executive shall begin employment on February 28, 2000, or such earlier date as agreed to by the parties (the “Employment Commencement Date”).  The initial term of this Agreement shall commence on the Effective Date and shall expire on October 17, 2018.  After that initial term, the Agreement shall automatically renew for successive 12-month periods thereafter on the same terms and conditions as set forth herein, unless either party provides written notice of non-renewal to the other party not less than ninety (90) days prior to the end of the then-current Term, or until the Agreement is otherwise terminated by the Company or Executive in accordance with the provisions of Section 6 (the duration of Executive's employment with the Company shall sometimes hereinafter be referred to as the “Term”).  
2.    Position and Responsibilities. Beginning with the Employment Commencement Date and continuing during the Term, Executive agrees to serve as Chief Financial Officer of the Company and its subsidiary Heritage-Crystal Clean, LLC.  In such capacity, Executive shall have such duties, authorities and responsibilities as are commensurate with such position.
3.    Standard of Care.  Beginning with the Employment Commencement Date and continuing during the Term, Executive (a) will devote Executive’s full working time and best efforts to the business and affairs of the Company; (b) will exercise the highest degree of loyalty and the highest standards of conduct in the performance of Executive’s duties; (c) will not, except with the Company's written consent, engage in any other business activity, whether or not such business activity is pursued for gain, profit or other pecuniary advantage; (d) will not engage, directly or indirectly, in any activity that is competitive with the Company’s business in any respect or make any preparations to engage in any competitive activities; and (e) will not take any action that deprives the Company of any business opportunities or otherwise act in a manner that conflicts with the best interests of the Company or that is detrimental to the business of the Company.
4.    Compensation and Benefits.  As remuneration for all services to be rendered by Executive during the Term, and as consideration for complying with the covenants herein, the Company shall pay and provide to Executive the following: 
4.1.    Annual Base Salary.  Beginning with the Employment Commencement Date and continuing during the Term, the Company shall pay Executive on a salary basis.  Executive’s initial Base Salary will be in the amount of Two Hundred Eighty-Five Thousand_Dollars ($285,000) on an annualized basis.  The Company will review the Base Salary approximately annually during the Term to determine, at the discretion of the Company, whether the Base Salary should be adjusted and, if so, the amount of such adjustment and the time at which the adjustment should take effect.  The term “Base Salary” as used in this Agreement shall refer to the Base Salary as in effect from time to time, including any adjustments.    
4.2.    Annual Performance-Based Compensation Opportunity.  Beginning with the Employment Commencement Date and continuing during the Term, the Company will provide Executive with an annual opportunity to earn performance-based compensation in the form of cash and/or shares of the Company’s common stock (non-restricted) based on the achievement of certain performance criteria as may be established by the Compensation Committee of the Company’s Board of Directors in its sole discretion in accordance with the provisions of the Company’s Omnibus Incentive Plan of 2008, as amended from time to time (the “2008 Incentive Plan”) and the Heritage-Crystal Clean, Inc. Performance-Based Annual Incentive Plan, as amended from time to time (“AIP”). The annual target bonus amount for such performance shares shall be calculated and provided to the Executive in the form and manner that the Company customarily follows as governed by the 2008 Incentive Plan and AIP.
4.3.    Employee Benefit Plans.  Executive shall be eligible to participate in any employee benefit plans and programs to which employees of the Company are generally entitled to participate, commensurate with Executive’s position with the Company and subject to the eligibility requirements and other terms and conditions of such plans and programs.  The Company, in its sole discretion, may change, amend or discontinue any of its employee benefit plans or programs at any time during Executive's employment with the Company, and nothing contained herein shall obligate the Company to institute, maintain or refrain from changing, amending or discontinuing any employee benefit plan or program.
4.4.    Vacation.    Executive shall be entitled to the number of vacation days in each fiscal year determined in accordance with the Company’s vacation policy in effect from time to time.  Executive shall also be entitled to all paid holidays and personal days given by the Company to its executives.
5.    Reimbursement of Business Expenses.  Subject to and consistent with the Company's expense reimbursement policies as in effect from time to time, the Company shall pay or reimburse Executive for all ordinary and necessary expenses, in a reasonable amount, which Executive incurs in performing Executive’s duties under this Agreement.  Such expenses shall be paid or reimbursed to Executive consistent with the expense reimbursement policies of the Company in effect from time to time and Executive agrees to abide by any such expense reimbursement policies. 
6.    Termination.
6.1.    Termination by Non-Renewal or Mutual Agreement.  If either party gives notice of an intention not to renew the term of this Agreement pursuant to Section 1 above, Executive’s employment shall terminate on the last day of the then-current Term.  The Company and Executive may also agree to terminate Executive's employment at any time by mutual written agreement executed by Executive and a duly authorized officer of the Company.  Upon termination of Executive's employment by non-renewal or by mutual written agreement, the Company’s obligation to pay or provide Executive compensation and benefits under this Agreement shall terminate, except the Company shall pay or provide Executive: (a) that portion of Executive’s Base Salary which is earned but unpaid through the termination date; (b) reimbursement of all expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed; and (c) vested benefits, if any, to which Executive may be entitled under the Company's employment benefit plans as of the date of termination (the foregoing subsections (a), (b), and (c) shall hereinafter be referred to collectively as the “Accrued Benefits”).  Other than the foregoing, the Company will have no further obligations to Executive under this Agreement. 
6.2.    Termination Due to Death.  If Executive dies during the Term, this Agreement shall terminate on the date of Executive’s death.  Upon the death of Executive, the Company’s obligation to pay and provide to Executive (or Executive’s estate or other legal successors) compensation and benefits under this Agreement shall immediately terminate, except the Company shall pay or provide Executive’s estate or other legal successor the Accrued Benefits.  Other than the foregoing, the Company shall have no further obligations to Executive (or Executive’s estate or other legal successors) under this Agreement. 
6.3.    Termination Due to Disability.  If Executive suffers a Disability, the Company may terminate Executive’s employment by providing written notice to Executive of the Company’s termination because of Disability specifying in such notice the effective termination date, and Executive’s employment will terminate at the end of the day on the termination date specified in the Company’s notice.  For purposes of this Agreement, the term “Disability” means either (a) when Executive is deemed disabled and entitled to benefits in accordance with any Company-provided long-term disability insurance policy or plan, if any is applicable, covering Executive, (b) the inability of Executive, because of injury, illness, disease or bodily or mental infirmity, to perform, with or without reasonable accommodation, the essential functions of Executive’s job for more than ninety (90) days during any period of three hundred sixty-five (365) days, or (c) upon the written determination by a physician selected by the Company that, because of an injury, illness, disease or bodily or mental infirmity, Executive is unable to perform, with or without reasonable accommodation, the essential functions of Executive’s job, and, as of the date of determination, such condition is reasonably expected to last for a period of more than ninety (90) days after the date of determination, based on the medical information reasonably available to such physician at the time of such determination.  In connection with any determination under the foregoing subpart (c), Executive hereby:  (i) consents to any examinations by any physician selected by the Company; (ii) agrees to furnish such medical information as may be requested by the Company or its selected physician; and (iii) waives any applicable physician-patient privilege that may arise because of any such examination.  Upon the termination of this Agreement because of Disability, the Company’s obligation to pay and provide Executive compensation and benefits under this Agreement will immediately terminate, except the Company will pay or provide Executive the Accrued Benefits.  Other than the foregoing, the Company will have no further obligations to Executive under this Agreement.
6.4.    Termination by the Company for Cause.  At any time during the Term, the Company may terminate this Agreement and Executive’s employment with the Company for Cause by providing Executive with written notice of the Company's termination for Cause specifying in such notice the termination date, and this Agreement and Executive's employment will terminate at the end of the day on the termination date specified in such notice.  For purposes of this Agreement, “Cause” means the occurrence of one or more of the following events:  (a) Executive’s conviction for, or pleading no contest to, a felony, any crime involving moral turpitude, or any crime that is injurious to the financial condition,  reputation or goodwill of the Company; (b) Executive’s misappropriation of any of the Company's property; (c) Executive’s engaging in any fraudulent or dishonest conduct in Executive’s dealings with, or on behalf of, the Company; (d) Executive’s engaging in any illegal conduct, except for minor infractions such as minor traffic violations, in the performance of Executive’s employment duties for the Company; (e) Executive’s failure or refusal to follow the lawful and material instructions of the Company's Board of Directors (other than any such failure or refusal resulting from Executive's incapacity due to physical or mental illness), if such failure or refusal continues for a period of thirty (30) days after the Company provides Executive with written notice stating the instructions which Executive has failed or refused to follow; (f) Executive’s material breach of Executive’s obligations under this Agreement or any other agreement with the Company (provided that if the Company in good faith determines that the breach is curable, the Company shall give Executive notice of the breach and thirty (30) days in which to cure the breach); (g) Executive’s material violation of any of the Company's written policies or procedures, including, without limitation, any Executive policies, business ethics policies or code of conduct policies, and such violation, if curable as determined by the Company in good faith, remains uncured for a period of thirty (30) days after the Company provides Executive with written notice of such violation; (h) Executive's engaging in any willful misconduct which is injurious to the financial condition, reputation or goodwill of the Company (provided that if the Company in good faith determines that the misconduct is curable, the Company shall give Executive notice of the misconduct and thirty (30) days in which to cure the misconduct); (i) Executive's gross or habitual neglect of Executive’s material employment duties or responsibilities if such neglect continues at any time after the Company provides Executive with written notice of such gross or habitual neglect; (j) Executive's failure to work on a full-time basis in fulfilling Executive’s employment duties hereunder, except for periods in which Executive is absent for scheduled vacations or for sickness, injury or other authorized leaves of absence, if such failure continues at any time after the Company provides Executive with written notice of such failure; or (k) Executive's misuse of alcohol or drugs which materially interferes with Executive's performance of Executive’s duties for the Company or which is injurious to the reputation or goodwill of the Company.  Upon termination of Executive’s employment by the Company for Cause, the Company’s obligation to pay or provide Executive compensation and benefits under this Agreement shall terminate, except the Company shall pay or provide Executive the Accrued Benefits.  Other than the foregoing, the Company shall have no further obligations to Executive under this Agreement.
6.5.    Termination by the Company without Cause.  At any time during the Term, the Company may terminate Executive’s employment with the Company without Cause for any reason or no reason by notifying Executive in writing of the Company’s termination without Cause, specifying in such notice the effective termination date, and Executive’s employment with the Company shall terminate at the end of the day on the termination date specified in the Company’s notice (or such other date as may be mutually agreed upon by the Company and Executive).  Upon termination of Executive’s employment by the Company without Cause, the Company’s obligation to pay and provide Executive compensation and benefits under this Agreement shall immediately terminate, except:  (a) the Company shall pay or provide Executive the Accrued Benefits; (b) the Company shall provide Executive with severance compensation in the form of salary continuation at the Base Salary rate in effect at the time of Executive's employment termination for a period of twelve (12) months; (c) the Company shall pay Executive an additional amount (the “Insurance Payment”) equal to twelve (12) times the monthly COBRA premium rate in effect for Executive’s health plan coverage tier at the time of Executive’s termination of employment; (d) if a bonus would otherwise have been payable to Executive for the year of Executive’s employment termination pursuant to the terms of the AIP under Section 4.2 above, Executive shall receive a prorated portion of that AIP bonus amount, based on the number of whole months in such year that Executive was employed prior to his employment termination; and (e) Executive will continue to vest for a period of twelve (12) months after the date of employment termination in any non-vested shares awarded prior to the employment termination under the 2008 Incentive Plan.  Subject to Section 6.8, the Company will pay: (1) the foregoing salary continuation severance compensation during the applicable severance period in accordance with the Company's customary payroll practices, (2) the Insurance Payment in a single lump sum payment within 30 days after the effective date of the Release Agreement under Section 6.8, and (3) the prorated AIP bonus, if any, on the date the AIP bonus is otherwise payable under the terms of the AIP.  All such payments shall be subject to all applicable payroll tax withholdings.  Other than the foregoing, the Company shall have no further obligations to Executive under this Agreement.  
6.6.    Termination by Executive for Good Reason.  At any time during the Term, Executive may terminate Executive's employment with the Company by giving the Company written notice of termination for Good Reason specifying in such notice the basis for the Good Reason termination.  For purposes of this Agreement, “Good Reason” means the occurrence of any of the following events without Executive's consent: (a) the Company demotes Executive or assigns Executive to duties that are materially inferior to and inconsistent with Executive's position, duties and responsibilities immediately prior to such assignment; (b) the Company materially breaches any material term of this Agreement; (c) the Company reduces Executive’s Base Salary other than a reduction that is effected in the context of material adverse conditions affecting the Company in which the Company has also effected similar salary reductions for the Chief Executive Officer and Chief Financial Officer; or (d) the Company eliminates or materially reduces the employee benefits provided to Executive, but only if such elimination or reduction is not applicable to the Chief Executive Officer and Chief Financial Officer; provided, however, the Company will have thirty (30) days from its receipt of any written notice of the Good Reason termination in which to take corrective action to cure the Good Reason, and if the Company does not cure the Good Reason, the Good Reason termination will be effective at the end of the thirtieth (30th) day after the Company receives the written notice of Good Reason termination; and provided further, however, for Executive to exercise his right to terminate for Good Reason, Executive must provide written notice of termination for Good Reason within sixty (60) days after the occurrence of the event giving rise to the basis for the Good Reason termination.  Upon Executive's termination of employment for Good Reason, the Company's obligation to pay or provide Executive compensation and benefits under this Agreement shall terminate, except:  (A) the Company shall pay or provide Executive the Accrued Benefits; (B) the Company shall provide Executive with severance compensation in the form of salary continuation at the Base Salary rate in effect at the time of Executive's employment termination for a period of twelve (12) months; (C) the Company shall pay Executive an additional amount (the “Insurance Payment”) equal to twelve (12) times the monthly COBRA premium rate in effect for Executive’s health plan coverage tier at the time of Executive’s termination of employment; (D) if a bonus would otherwise have been payable to Executive for the year of Executive’s employment termination pursuant to the terms of the AIP under Section 4.2 above, Executive shall receive a prorated portion of that AIP bonus amount, based on the number of whole months in such year that Executive was employed prior to his employment termination; and (E) Executive will continue to vest for a period of twelve (12) months after the date of employment termination in any non-vested shares awarded prior to the employment termination under the 2008 Incentive Plan.. Subject to Section 6.8, the Company will pay: (1) the foregoing salary continuation severance compensation during the applicable severance period in accordance with the Company's customary payroll practices, (2) the Insurance Payment in a single lump sum payment within 30 days after the effective date of the Release Agreement under Section 6.8, and (3) the prorated AIP bonus, if any, on the date the AIP bonus is otherwise payable under the terms of the AIP.  All such payments shall be subject to all applicable payroll tax withholdings.  Other than the foregoing, the Company shall have no further obligations to Executive under this Agreement.
6.7.    Termination by Executive without Good Reason.  At any time during the Term, Executive may terminate Executive’s employment with the Company without Good Reason by giving the Company written notice of termination without Good Reason, specifying in such notice a termination date not less than thirty (30) calendar days after the giving of the notice (the “Executive’s Notice Period”), and Executive’s employment with the Company shall terminate at the end of the day on the last day of Executive’s Notice Period; provided, however, that in response to Executive’s notice of termination without Good Reason, the Company shall have the right to terminate Executive’s employment with the Company at any time during the Executive’s Notice Period.  Upon termination of Executive’s employment with the Company under this Section 6.7, whether at the end of Executive’s Notice Period or earlier as designated by the Company, the Company’s obligation to pay Executive compensation and benefits under this Agreement shall immediately terminate, except the Company shall pay or provide Executive with the Accrued Benefits.  Other than the foregoing, the Company shall have no further obligations to Executive under this Agreement.
6.8.    Severance Release.  Executive acknowledges and agrees that the Company’s payment of the severance and other compensation pursuant to Section 6.5 or Section 6.6 shall be deemed to constitute a full settlement and discharge of any and all obligations of the Company to Executive arising out of this Agreement, Executive’s employment with the Company and/or the termination of Executive’s employment with the Company.  Executive further acknowledges and agrees that as a condition to receiving any of the severance and other compensation pursuant to Section 6.5 or Section 6.6, Executive will execute, deliver to the Company, and not revoke a release agreement in a form prepared by, and satisfactory to, the Company (the "Release Agreement") pursuant to which Executive will release and waive, to the fullest extent permitted by law, all claims against the Company, its affiliates, and all of its and their present and/or former owners, officers, directors, members, shareholders, employees, agents, attorneys, insurers, representatives, employee benefit plans and their fiduciaries, both individually and in their representative capacities, including, without limitation, all claims arising out of this Agreement, Executive's employment with the Company, and/or the termination of Executive's employment with the Company; provided, however, that the Release Agreement shall not affect or release (a) any claim for the Accrued Benefits, (b) any rights to the severance and other compensation under Section 6.5 or Section 6.6, as applicable; and (c) any rights Executive may have with respect to vested benefits under any employee benefit plans or programs of the Company (except any severance plan).  The severance and other compensation described in Section 6.5 or Section 6.6 is in lieu of any severance benefits under any severance policy or plan the Company may have now or in the future, and Executive acknowledges that Executive is not entitled to any other severance benefits.
6.9.    Effect of Termination of Employment.  In the event Executive’s employment with the Company terminates for any reason (including, without limitation, pursuant to Sections 6.1 – 6.7 herein), Executive agrees and covenants that Executive will immediately resign, and will be deemed to have resigned from, any and all positions Executive may hold with the Company or any of its subsidiaries or affiliates. 
6.10.    Effect of Executive's Death on Severance Benefits.  If Executive dies during the period of time Executive is entitled to receive the severance and other benefits under Section 6.5 or Section 6.6, the Company shall pay the remaining severance and other benefits to Executive's estate (or other legal successor).
6.11.    Separation from Service.  Whenever used in this Agreement, the word “terminate” or “termination” in connection with Executive's employment shall mean a “separation from service” of Executive from the Company and its affiliates within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and Treasury Regulation Section 1.409A-1(h), and Executive's termination date shall be the date of such separation from service.
7.    Non-Disclosure of Confidential Information.  For purposes of this Agreement, the term “Confidential Information” means any and all of the Company’s (and its subsidiaries' or affiliates') trade secrets, confidential and proprietary information and all other non-public information and data of or about the Company (and its affiliates) and its business, including, without limitation, lists of customers, information pertaining to customers, marketing plans and strategies, information pertaining to suppliers, information pertaining to prospective suppliers, pricing information, engineering and technical information, software codes, cost information, data compilations, research and development information, business plans, financial information, personnel information, information received from third parties that the Company has agreed to keep confidential, and information about prospective customers or prospective products and services, whether or not reduced to writing or other tangible medium of expression, including, without limitation, work product created by Executive in rendering services for the Company.  During Executive’s employment with the Company and thereafter, Executive will not use or disclose to others any of the Confidential Information, except (a) in the course of Executive’s work for and on behalf of the Company, (b) with the prior written consent of the Company or (c) as required by law or judicial process, provided Executive promptly notifies the Company in writing of any subpoena or other judicial request for disclosure involving confidential information or trade secrets, and cooperates with any effort by the Company to obtain a protective order preserving the confidentiality of the confidential information or trade secrets.  Executive agrees that the Company owns the Confidential Information and Executive has no rights, title or interest in any of the Confidential Information.  Additionally, Executive will abide by the Company’s policies protecting the Confidential Information, as such policies may exist from time to time.  At the Company’s request or upon termination of Executive’s employment with the Company for any reason, Executive will immediately deliver to the Company any and all materials (including all copies and electronically stored data) containing any Confidential Information in Executive’s possession, custody or control.  Upon termination of Executive’s employment with the Company for any reason, Executive will, if requested by the Company, provide the Company with a signed written statement disclosing whether Executive has returned to the Company all materials (including all copies and electronically stored data) containing any Confidential Information previously in Executive’s possession, custody or control.  Executive's confidentiality/non-disclosure obligations under this Agreement continue after the termination of Executive's employment with the Company for any reason.  With respect to any particular trade secret information, Executive's confidentiality/non-disclosure obligations shall continue as long as such information constitutes a trade secret under applicable law.  With respect to any particular Confidential Information that does not constitute a trade secret, Executive’s confidentiality/non-disclosure obligations shall continue as long as such information remains confidential, and shall not apply to information that becomes generally known to the public through no fault or action of Executive or others who were under confidentiality obligations with respect to such information.  Executive acknowledges and agrees that Executive’s obligations under this Section shall survive the expiration or termination of this Agreement and the cessation of Executive’s employment with the Company for whatever reason.  Executive further acknowledges and agrees that Executive’s obligations under this Section shall be construed as independent covenants and that no breach of any contractual or legal duty by the Company shall be held sufficient to excuse or terminate Executive's obligations under this Section or to preclude the Company from enforcing this Section.
8.    Restrictive Covenants.  
8.1.    Definitions.  For purposes of this Agreement, the following terms have the following meanings:
(a)    “Company’s Customers” means: (i) any person or entity to whom the Company (or any of its subsidiaries or affiliates) is selling or providing any products and/or services as of the date of termination of Executive's employment with the Company; and/or (ii) any person or entity to whom the Company (or any of its subsidiaries or affiliates) sold or provided any products and/or services at any time during the Term; and/or (iii) any person or entity to whom the Company (or any of its subsidiaries or affiliates) sold or provided any products and/or services at any time during the twelve (12) months immediately preceding the termination of Executive’s employment with the Company.
(b)    “Competing Products/Services” means:  (i) any products and/or services that are similar to and/or competitive with any of the products and/or services that the Company is developing, producing, offering and/or providing as of the termination of Executive’s employment with the Company; and/or (ii) any products and/or services that are competitive with the products and/or services that are being developed, produced, offered, sold or provided by the Company as of termination of Executive’s employment with the Company in that such competitive products and/or services would serve as a substitute for, and would displace or diminish a customer’s need for, any of the Company’s products and/or services.
(c)    “Competitive Business” means any business that develops, produces, sells and/or provides any Competing Products/Services and/or is competitive with the business of the Company.
(d)    “Prohibited Capacity” means:  (a) in the same or similar capacity or function to that in which Executive worked for the Company at any time during the thirty-six (36) months immediately preceding the termination of Executive’s employment with the Company; (b) in any sales or sales management capacity or function; (c) in any executive or officer capacity or function; (d) in any managerial capacity or function; (e) in any business consulting capacity or function; (f) in any ownership capacity, except Executive may own as a passive investment shares of any class of securities regularly traded on a national stock exchange or other public market, (g) in any capacity or function in which Executive likely would inevitably use or disclose the Company’s trade secrets or Confidential Information; or (h) in any other capacity or function in which Executive’s knowledge of the Confidential Information would facilitate or assist Executive’s work for the Competitive Business.  
(e)    “Restricted Geographic Area” means any state in which the Company currently sells or otherwise provides its products or services to the Company’s Customers, or in which it previously sold or otherwise provided its products or services to the Company’s Customers during any of the time periods specified in subparts (i), (ii) and (iii) of Section 8.1(a) above.
(f)    “Restricted Time Period” means the period during Executive’s employment with the Company and for twelve (12) months after the termination of Executive's employment for any reason.
8.2.    Non-Competition.  During the Restricted Time Period, Executive will not within the Restricted Geographic Area engage in (including, without limitation, being employed by, working for, or rendering services to) any Competitive Business in any Prohibited Capacity; provided, however, if the Competitive Business has multiple divisions, lines or segments, some of which are not competitive with the business of the Company, nothing herein shall prohibit Executive from being employed by, working for or assisting only that division, line or segment of such Competitive Business that is not competitive with the business of the Company provided that Executive's work for such non-competitive division, line or segment of the Competitive Business does not involve any Competing Products/Services; and provided further, however, nothing herein shall be construed to prohibit Executive from the practice of law. 
8.3.    Customer Restrictions.  
(a)    During the Restricted Time Period, Executive will not provide, sell, market, attempt to provide, sell or market, or assist any person or entity in the sale or provision of, any Competing Products/Services to any of the Company’s Customers with respect to whom, at any time during the twelve (12) months immediately preceding the termination of Executive’s employment with the Company, Executive had any sales or service contact on behalf of the Company, Executive had any business contact on behalf of the Company, Executive had any role (including without limitation any supervisory or managerial responsibility) on behalf of the Company in providing products or services, or Executive had access to, or gained knowledge of, any Confidential Information concerning the Company’s business with such customer, or otherwise solicit or communicate with any such customers for the purposes of selling or providing any Competing Products/Services.     
(b)    During the Restricted Time Period, Executive will not provide, sell, market, assist in the provision, selling or marketing of, or attempt to provide, sell or market any Competing Products/Services to any of the Company’s Customers located in the Restricted Geographic Area or otherwise solicit or communicate with any of the Company’s Customers located in the Restricted Geographic Area for the purpose of selling, marketing or providing, assisting in the provision, selling or marketing of, or attempting to sell, market or provide any Competing Products/Services. 
(c)    During the Restricted Time Period, Executive will not urge, induce or seek to induce any of the Company’s Customers to terminate their business with the Company or to cancel, reduce, limit or in any manner interfere with the Company’s Customers’ business with the Company.
8.4.    Non‐Interference with Contractors and Vendors.  During the Restricted Time Period, Executive will not urge, induce or seek to induce any of the Company’s independent contractors, subcontractors, distributors, brokers, consultants, sales representatives, vendors, suppliers or any other person or entity with whom the Company has a business relationship to terminate their relationship with, or representation of, the Company or to cancel, withdraw, reduce, limit or in any manner modify any such person’s or entity’s business with, or representation of, the Company. 
8.5.    Employee Restrictions.  During the Restricted Time Period, Executive will not solicit, recruit, hire, employ, attempt to hire or employ, or assist any person or entity in the recruitment or hiring of, any person who is an employee of the Company, or otherwise urge, induce or seek to induce any person to terminate his/her employment with the Company.  
8.6.    Non-Disparagement.  During the Restricted Time Period, Executive will not make or publish any statements or comments that disparage or injure the reputation or goodwill of the Company or any of its officers, directors, or employees, including, but not limited to, making or publishing any comments or statements to the Company’s customers, distributors or employees that disparage the Company or its products and/or services or that otherwise injure or diminish the Company’s relationship with such customers, distributors or employees; provided, however, nothing herein shall prohibit Executive from providing any information that may be required or compelled by law or legal process. 
8.7.    Direct or Indirect Activities.  Executive acknowledges and agrees that the covenants contained in this Section 8 prohibit Executive from engaging in certain activities directly or indirectly, whether on Executive’s own behalf or on behalf of any other person or entity, and regardless of the capacity in which Executive is acting, including without limitation as an employee, independent contractor, owner, partner, officer, agent, consultant, or advisor.
8.8.    Survival of Restrictive Covenants.  Executive acknowledges and agrees that Executive’s obligations under this Section 8 shall survive the expiration or termination of this Agreement and the cessation of Executive’s service with the Company for whatever reason.  Executive further acknowledges and agrees that Executive’s restrictive covenant obligations under this Section 8 shall be construed as independent covenants and that no breach of any contractual or legal duty by the Company shall be held sufficient to excuse or terminate Executive's restrictive covenant obligations under this Section 8 or to preclude the Company from enforcing this Section 8.  
8.9.    Extension.  In the event Executive violates any of the restrictive covenants contained in this Section 8, the duration of all restrictive covenants (and the Restricted Time Period) shall automatically be extended by the length of time during which Executive was in violation of any of the restrictive covenants.
8.10.    Severability; Reformation of Restrictions.  Although Executive and the Company consider the restrictions contained in this Section 8 to be reasonable, particularly given the competitive nature of the Company’s business and Executive’s position with the Company, Executive and the Company acknowledge and agree that:  (a) if any covenant, subsection, portion or clause of this Section 8 is determined to be unenforceable or invalid for any reason, such unenforceability or invalidity shall not affect the enforceability or validity of the remainder of the Agreement; and (b) if any particular covenant, subsection, provision or clause of this Section 8 is determined to be unreasonable or unenforceable for any reason, including, without limitation, the time period, geographic area, and/or scope of activity covered by any restrictive covenant, such covenant, subsection, provision or clause shall automatically be deemed reformed such that the contested covenant, subsection, provision or clause shall have the closest effect permitted by applicable law to the original form and shall be given effect and enforced as so reformed to whatever extent would be reasonable and enforceable under applicable law.  Any court interpreting any restrictive covenant provision of this Agreement shall, if necessary, reform any such provision to make it enforceable under applicable law.
9.    Company Property.  Executive acknowledges and agrees that all tangible materials, equipment, documents, copies of documents, data compilations (in whatever form), and electronically created or stored materials that Executive receives or makes in the course of his employment with the Company (or with the use of Company time, materials, facilities or trade secrets or confidential information) are and shall remain the property of the Company.  Upon the termination of Executive’s service with the Company, or at the Company’s request, Executive shall immediately deliver to the Company (i) any and all memoranda, notes, records, drawings, manuals, computer programs, documentation, diskettes, computer tapes, electronic data (in whatever form or media), and all copies thereof, in Executive’s possession or under Executive’s control, whether prepared by Executive or others, containing any Confidential Information; and (ii) any and all property or equipment belonging to the Company, including, without limitation, keys, access cards, computers, files and documents.  Executive acknowledges and agrees that Executive’s obligations under this Section shall survive the expiration or termination of this Agreement and the cessation of Executive’s employment with the Company for whatever reason.
10.    Remedies.  Executive acknowledges that a breach or threatened breach by Executive of Section 7, Section 8 or Section 9 of this Agreement will give rise to irreparable injury to the Company and that money damages will not be adequate relief for such injury and, accordingly, Executive agrees that the Company shall be entitled to obtain equitable relief, including, but not limited to, temporary restraining orders, preliminary injunctions and/or permanent injunctions, without having to post any bond or other security, to restrain or prohibit such breach or threatened breach, in addition to any other legal remedies which may be available, including the recovery of money damages.  In addition to all other relief to which it shall be entitled, the prevailing party shall be entitled to recover from the non-prevailing party all litigation costs and attorneys’ fees incurred by the prevailing party in any action or proceeding relating to Section 7, Section 8 and/or Section 9 of this Agreement in which the prevailing party prevails in any respect, including, without limitation, any action in which the prevailing party seeks enforcement of Section 7, Section 8 and/or Section 9 of this Agreement or seeks relief from the non-prevailing party’s violation of Section 7, Section 8 and/or Section 9 of this Agreement.  
11.    Intellectual Property.  
11.1.    Executive agrees that any invention, development, concept, enhancement, process, method, improvement or any other creation that Executive, alone or jointly with others, invents, creates or develops at any time during Executive's employment with the Company and relating to the Company's business or future business which the Company had under consideration during Executive's employment (collectively "Inventions") shall be promptly and fully disclosed by Executive to the Company and shall be the Company's exclusive property.  Executive hereby assigns and conveys to the Company all rights, title and interest in the Inventions.  Executive further agrees to promptly deliver to the Company all papers, files, data and other materials relating to any such Inventions.  Executive shall, at the request of the Company and without royalty or other consideration, execute, acknowledge and deliver to the Company at its expense such written documents or instruments as may be necessary to further memorialize the assignment to the Company of all patents and other rights in such Inventions and the vesting of all right, title and interest to such Inventions in the Company.  Notwithstanding any other provision of this section to the contrary, this section does not apply to an invention for which no equipment, supplies, facility, or Confidential Information of the Company was used and which was developed by Executive entirely on Executive’s own time unless:  (a) the invention relates (i) to the business of the Company, or (ii) to the Company’s actual or demonstrably anticipated research or development; or (b) the invention results from any work performed by Executive for the Company.
11.2.    All written, graphic or recorded material and all other works of authorship fixed in a tangible medium of expression that Executive, alone or jointly with others, makes or creates at any time during Executive's employment with the Company and relating to the Company's business, actual or contemplated, shall be the exclusive property of the Company (collectively "Works").  The Company will have the exclusive right to copyright such Works.  Executive agrees that if any Works created by Executive while employed with the Company, whether or not created at the direction of the Company, is copyrightable, it will be a "work made for hire," as that term is defined in the copyright laws of the United States.  If, for any reason, any copyrightable Works created by Executive are excluded from that definition, Executive hereby assigns and conveys to the Company all right, title and interest (including any copyright and renewals) in such Works.
11.3.    Executive agrees that the Company and its licensees are not required to designate Executive as author, or inventor or developer of any Works or Inventions when distributed or otherwise.  Executive hereby waives and agrees not to assert any and all rights in any Inventions and Works.  Executive agrees that the Company and its licensees shall have sole discretion with regard to how and for what purposes any Inventions or Works are used or distributed.  Executive will sign documents of assignment, declarations and other documents and take all other actions reasonably required by the Company, at the Company's expense, to perfect and enforce any of its proprietary rights in any of the Inventions or Works.
12.    Assignment.  
12.1.    Assignment by Company.  The rights and obligations of the Company under this Agreement shall inure to the benefit of and be binding upon any and all successors and assigns of the Company, including without limitation by asset assignment, merger, consolidation or other reorganization.  As used in this Agreement, “Company” shall mean the Company has hereinbefore defined and any successor to its business and/or assets which assumes and agrees to perform this Agreement by operation of law, or otherwise.
12.2.    Non‐Assignment by Executive.  The services to be provided by Executive to the Company hereunder are personal to Executive, and Executive’s duties may not be assigned by Executive.
13.    Notice.  Any notice required or permitted under this Agreement shall be in writing and either delivered personally or sent by nationally recognized overnight courier, express mail, or certified or registered mail, postage prepaid, return receipt requested, at the following respective address unless the party notifies the other party in writing of a change of address:
If to the Company:

Heritage-Crystal Clean, Inc.
5400 West 86th Street
Indianapolis, IN  46268
Attention: Chief Executive Officer

If to Executive:

Mark DeVita
579 Flora Drive
Algonquin, IL 60102

A notice delivered personally shall be deemed delivered and effective as of the date of delivery.  A notice sent by overnight courier or express mail shall be deemed delivered and effective the next business day after it is deposited with the postal authority or commercial carrier.  A notice sent by certified or registered mail shall be deemed delivered and effective three (3) days after it is deposited with the postal authority.
14.    Miscellaneous. 
14.1.    Entire Agreement.  This Agreement constitutes the entire agreement of the parties with respect to the subjects addressed herein, and supersedes any prior agreements, understandings, or representations, oral or written, on the subjects addressed herein. 
14.2.    Modification.  This Agreement shall not be varied, altered, modified, canceled, changed, or in any way amended except by (a) mutual agreement of the parties in a written instrument executed by Executive and a duly authorized officer or member of the Board of Directors of the Company or (b) reformation by a court as provided in Section 8.10. 
14.3.    Tax Withholding.  The Company may withhold from any compensation or benefits payable under this Agreement all federal, state, city, or other taxes as may be required pursuant to any law or governmental regulation or ruling.
14.4.    Contractual Rights to Benefits.  Any benefits payable under this Agreement shall be paid solely from the general assets of the Company.  Neither Executive nor Executive's estate shall have interest in any specific assets of the Company under the terms of this Agreement.  This Agreement shall not be considered to create an escrow account, trust fund or other funding arrangement of any kind between Executive and the Company.  Nothing herein contained shall require or be deemed to require, or prohibit or be deemed to prohibit, the Company to segregate, earmark or otherwise set aside any funds or other assets, in trust or otherwise, to provide for any payments to be made or required hereunder. 
14.5.    No Waiver.  Failure to insist upon strict compliance with any of the terms, covenants or conditions of this Agreement shall not be deemed a waiver of such term, covenant or condition, nor shall any waiver or relinquishment of any right or power hereunder at any one or more times be deemed a waiver or relinquishment of such right or power at any other time or times.
14.6.    Governing Law; Choice of Forum.  To the extent not preempted by federal law, the provisions of this Agreement shall be construed and enforced in accordance with the laws of the State of Illinois, notwithstanding any state’s choice-of-law or conflicts-of-law rules to the contrary.  The Company and Executive further acknowledge and agree that this Agreement is intended, among other things, to supplement the provisions of the Uniform Trade Secrets Act, as amended from time to time, and the duties Executive owes to the Company under the common law, including, but not limited to, the duty of loyalty.  The parties agree that any legal action relating to this Agreement shall be commenced and maintained exclusively before any appropriate state court of record in Cook County, Illinois, or in the United States District Court for the Northern District of Illinois, Eastern Division, and the parties hereby submit to the personal jurisdiction and venue of such courts and waive any right to challenge or otherwise object to personal jurisdiction or venue in any action commenced or maintained in such courts. 
14.7.    No Conflicting Agreements.  Executive represents and warrants to the Company that:  (a) Executive’s employment by the Company and the performance of Executive’s employment duties will not constitute a breach of any agreements to which Executive is a party, including without limitation any employment or non-competition agreement with any former employer; and (b) Executive has not provided and will not provide to the Company, and will not use or disclose during the performance of Executive’s employment services for the Company, any documents, materials or information of any third party subject to any legally enforceable restrictions or obligations as to confidentiality or secrecy.
14.8.    Compliance with Section 409A of the Code.  The intent of the parties is that payments and benefits under this Agreement comply with Section 409A of the Code (“Code Section 409A”), to the extent subject thereto, and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted and be administered to be in compliance therewith.  Notwithstanding anything contained herein to the contrary, to the extent required in order to avoid accelerated taxation and/or tax penalties under Code Section 409A, Executive shall not be considered to have terminated employment with the Company for purposes of this Agreement until Executive would be considered to have incurred a “separation from service” from the Company within the meaning of Code Section 409A.  Any payments described in this Agreement that are due within the “short-term deferral period” (as defined in Code Section 409A) shall not be treated as deferred compensation unless applicable law requires otherwise.  Each amount to be paid or benefit to be provided to Executive pursuant to this Agreement that constitutes deferred compensation subject to Code Section 409A shall be construed as a separate identified payment for purposes of Code Section 409A.  Notwithstanding anything to the contrary in this Agreement, to the extent that any payments to be made in connection with Executive’s separation from service would result in the imposition of any individual excise tax and late interest charges imposed under Code Section 409A, the payment shall instead be made on the first business day after the earlier of (a) the date that is six (6) months following such separation from service or (b) the date of Executive’s death.
14.9.    Construction.  This Agreement is the result of negotiations between the parties, and neither party shall be deemed to be the drafter of this Agreement.  The language of this Agreement shall in all cases be construed as a whole, according to its fair meaning, and not strictly for or against either party.  This Agreement shall be interpreted and construed without any presumption or inference based upon or against the party causing this Agreement to be drafted.
14.10.    Voluntary Agreement.  Executive acknowledges:  (a) Executive has read this Agreement; (b) Executive has been given ample time to consider this Agreement; (c) Executive has been given the opportunity to consult with Executive's own attorney or other advisors if Executive so chooses; and (d) Executive is entering into this Agreement knowingly and voluntarily intending to be legally bound.  
14.11.    Counterparts.  This Agreement may be executed in one (1) or more counterparts, each of which shall be deemed to be an original, but all of which together will constitute one and the same Agreement.  Signatures transmitted by facsimile or other electronic means shall be effective the same as original signatures for execution of this Agreement.
IN WITNESS WHEREOF, Executive and the Company have executed this Agreement, intending it to be effective as of the Effective Date.
HERITAGE-CRYSTAL CLEAN, INC.                EXECUTIVE

By: /s/ Brian Recatto                        By: /s/ Mark DeVita
            
Brian Recatto                             Mark DeVita

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]